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ABSTRACT 
 
 Fe-S clusters are one major type of the sulfur-containing cofactors, which conduct 
essential functions in organisms. The Suf pathway is one of the three main pathways for 
the biosynthesis of Fe-S clusters. In E. coli, the Suf pathway is utilized under iron limitation 
and oxidative stress. This ability is important for pathogens to survive. Also, the Suf 
pathway is found to be exclusive in bacteria, so it is a good target for novel antibiotic 
design. SufS is a cysteine desulfurase in the Suf pathway to extract sulfur from L-cysteine. 
It needs the enhancement of SufE. To better understand the catalytic mechanism of the 
reaction between SufS and L-cysteine in the presence of SufE, we applied 31P NMR, 
stopped flow spectroscopy, and site directed mutagenesis. The results show that binding of 
SufE causes a conformational change of the pyridoxal 5’- phosphate (PLP) cofactor in 
SufS. The reaction of L-cysteine and PLP is a biphasic process including the fast phase 
(formation of external aldimine) and slow phase (shift to ketimine). The binding of SufE 
facilitates the formation of the ketimine. We mutated SufS H123A, which removed the 
enhancement of SufE to the activity of SufS and the formation of Cys ketimine. Finally, 
binding of SufE increased the formation of the persulfide in SufS. Characterization of the 
interaction of SufS and SufE may provide insight for the design of protein-protein 
interaction inhibitor. We made the Y345A/D346A mutation in SufS. We applied PLP 
quantification, analytical gel filtration, UV-visible absorption spectroscopic analysis and 
vii 
circular dichroism to confirm this mutant still keeps the structural integrity. The basal 
activity of SufS Y345A/D346A is similar as that of wild-type SufS. However, SufE cannot 
enhance the activity of this mutant. The result of the isothermal titration calorimetry (ITC) 
shows that there is reduced interaction between this mutant and SufE. Based on the research 
above, a structural modeling of the SufS-SufE interaction was made through protein-
protein docking, which clarifies more details in this interaction. SufS has an essential 
cofactor PLP that can be a target for the PLP-based inhibitor like DCS and LCS. To 
investigate if DCS/LCS can inhibit the activity of SufS, we checked the activity of SufS in 
the presence of either D-cycloserine (DCS) or L-cycloserine (LCS). The results show that 
there is a dose-dependent inhibition of SufS activity by DCS. The 50% inhibitory 
concentration (IC50) was calculated to be 1.98 mM. A dose-dependent inhibition of SufS 
by LCS was also observed and the IC50 is 306.1 µM Compared with DCS, LCS shows 
much better inhibitory effects. The small-molecular docking shows that the nitrogen of 
DCS to start the nucleophilic attack towards the Schiff base of the PLP and Lys226 is far 
away from its target, which is not a proper orientation for the transimination reaction. The 
docking of LCS shows that the nitrogen of LCS for the nucleophilic attack is close to the 
Schiff base of Lys226 and PLP, which is a proper orientation for the following 
transimination reaction. The UV-visible absorption spectra of SufS and DCS shows the 
degradation of internal aldimine and a new intermediate at 380 nm is formed. The spectrum 
of LCS shows the 380 nm peak is reduced but the 320 nm peak keeps growing, which 
indicates the intermediate at 320 nm is a stable adduct and it is rarely get rescued by 
excessive L-cysteine. A reaction mechanism is proposed to depict the reaction between 
SufS and DCS/LCS.
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CHAPTER 1 
INTRODUCTION 
 
            Fe-S cluster and suf operon             
            Iron-sulfur (Fe-S) clusters are essential metal cofactors used in a wide-range of 
critical biological pathways, including respiration, photosynthesis, nitrogen fixation, and 
DNA repair.  Fe-S clusters consist of iron in the Fe2+ or Fe3+ oxidation states bound to 
sulfide (S2-).  Different cluster types are referred to base on the ratios of iron and sulfide 
present in those clusters, for example [2Fe-2S] or [4Fe-4S] clusters (Figure 1.1).  Larger, 
more complex Fe-S clusters can also be found in some metalloproteins.1  For example the 
P-cluster of the nitrogenase complex contains a [7Fe-8S] cluster.  Fe-S clusters can be 
combined with other metals and small molecules to form more complex cofactors, such as 
the FeMo cofactor also found in nitrogenase that contains [Mo-3Fe-3S] cluster, a [4Fe-3S] 
cluster bridged by 3 additional sulfide ligands, and a central carbon atom as part of a Fe6-
carbide species.2, 3 
            Despite their ubiquity across all domains of life, Fe-S clusters represent a potential 
Achilles heel for cells, especially those that grow in the presence of oxygen.  Solvent 
exposed [4Fe-4S] cuboidal Fe-S clusters that contain mixed oxidation states of Fe are 
sensitive to oxidation by oxygen or reactive oxygen species formed in the cell.4-6 
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Figure 1.1. Structure of the E. coli succinate dehydrogenase complex with Fe-S clusters 
highlighted as spheres.  Ubiquinone, flavin, and heme as well as Fe-S cluster ligands are 
shown as sticks. 
  
3 
Furthermore, iron availability in the environment greatly decreases in the presence of 
oxygen due to the oxidation of Fe2+ to Fe3+ and the formation of insoluble ferric hydroxide  
compounds.  The scarcity of iron can make it difficult for a cell to maintain adequate levels 
of iron metalloproteins, especially in the case of Fe-S cluster proteins.  Finally, Fe-S 
clusters can be poisoned by other thiophilic metals, such as copper and cobalt, that compete 
with iron for binding to exposed sulfur ligands.7-9  Due to the sensitive nature of some types 
of Fe-S clusters, it is likely that cells growing in the presence of oxygen must constantly 
repair and/or resynthesize Fe-S cluster cofactors to keep up with the turnover of mature Fe-
S metalloproteins.   
            The selective pressure to maintain adequate levels of essential Fe-S metalloproteins 
has led to the evolution of so-called Fe-S cluster biogenesis systems.  These pathways, 
often encoded as polycistronic mRNA transcribed from operons in bacteria and Archaea, 
catalyze the in vivo formation of Fe-S clusters from iron and sulfide building blocks.  Fe-
S cluster biogenesis systems also include Fe-S cluster trafficking proteins that direct the de 
novo clusters to the appropriate Fe-S metalloprotein in the cell.  Multiple Fe-S cluster 
biogenesis systems have been identified, each with their own peculiar phylogenetic 
distribution and (in eukarya) sub-cellular location.   
            Phylogenetic analysis reveals that the most ancient form of the suf operon consists 
of just two genes, sufB and sufC (Figure 1.2).10, 11  The sufBC locus is primarily found in 
the earliest rooting lineages of the Archaea and Bacteria.  It appears that selection for the 
addition of other suf genes occurred throughout evolution, possibly due to changing 
environmental pressures resulting from oxygenation of the atmosphere and concomitant 
alterations in iron and sulfur metabolism.10  The most complex suf operons can contain as  
4 
 
 
 
Figure 1.2. Model of the core components of Suf pathway: SufB and SufC. 
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many as 5-6 genes in addition to sufB and sufC.  The exact roles for some of the Suf proteins 
are still being elucidated but much progress has been made in characterizing the core 
process of sulfur donation, de novo cluster formation, and downstream Fe-S cluster 
trafficking.  While the simplest and phylogenetically most ancient suf operon (sufBC) 
appears in the Archaea, most of the progress in characterizing the Suf system at the genetic 
and biochemical levels has occurred in organisms with the more complex Suf systems, 
especially in the gamma proteobacteria.12   
 
            Regulation and physiological role of Suf in Proteobacteria 
            The Suf pathway was first identified as part of the Fur and OxyR regulons in the 
gammaproteobacterium, Escherichia coli.13, 14  Fur is a global transcriptional regulator of 
iron homeostasis while OxyR controls the transcription of genes used for H2O2 stress 
defense. Since its initial discovery, the E. coli Suf pathway has been well characterized at 
the biochemical, genetic, and regulatory levels.  Furthermore, the Suf pathway has been 
shown to work under oxidative stress and iron starvation conditions in the 
gammaproteobacteria, although this property may or may not be maintained in other 
bacteria.15-20 
            The biosynthesis of Fe-S clusters in E. coli is somewhat peculiar as the organism 
uses either the housekeeping Isc system (which does not appear to be particularly stress-
resistant) or the stress-responsive Suf pathway15, 19, 20  The complete absence of both 
systems is lethal to E. coli.11, 19  The lethality appears to stem from loss of Fe-S clusters in 
specific metalloenzymes of the isoprenoid biosynthesis pathway as lethality can be 
bypassed if an alternate pathway is provided that does not rely on Fe-S cluster cofactors.21 
6 
             In E. coli, the Suf pathway consists of SufA, SufB, SufC, SufD, SufE, and SufS 
organized in an operon as sufABCDSE.  E. coli tightly controls transcription of the suf 
operon through the coordinated action of multiple regulatory proteins (Figure 1.3).  Under 
non-stressed conditions, Fur-Fe2+ binds to the suf promoter to repress the transcription of 
the suf operon.13, 19, 22  During iron starvation Fur converts to its iron-free (apo) form, which 
does not efficiently repress target promoters, and releases suf repression allowing increased 
transcription of the suf operon.  Oxidative stress activates OxyR, which increases suf 
transcription in conjunction with the DNA-bending protein IHF.14, 16, 19, 22  Later it was also 
discovered that IscR regulates the suf operon.  IscR is an Fe-S cluster binding transcription 
factor which regulates at least 40 genes in E. coli, including the isc and suf operons.23, 24  
Apo-IscR binds the suf promoter to activate transcription of the suf operon in response to 
oxidative stress, iron limitation, and other conditions that perturb Fe-S cluster biogenesis 
by the Isc pathway22, 25-28  Coordination of isc and suf expression is also facilitated by the 
small RNA RyhB.  The expression of ryhB is repressed by Fur-Fe2+ when iron is replete in 
the cell.29  Under limited iron, apo-Fur loses the ability to bind DNA, which releases ryhB 
repression. The isc mRNA transcript basepairs with RyhB causing it to be degraded when 
iron is limited.30, 31  The sum of this complex regulatory network is that Fe-S cluster 
biogenesis switches from the Isc to the Suf pathway under conditions of iron limitation and 
oxidative stress in E. coli.  The switch to the Suf pathway in these organisms is supported 
by genetic studies demonstrating that most ∆suf deletion strains are more sensitive to 
oxidative stress, iron starvation, and metal poisoning.7, 11, 17-20, 32  All of these defects are 
linked to disruption of Fe-S cluster biogenesis by the stress condition if the Suf machinery 
is missing. 
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Figure 1.3. Regulation of Fe-S cluster assembly pathways in E. coli by IscR and OxyR. 
(A) Regulation by holo IscR and Fur under normal condition. (B) Regulation by apo IscR 
and OxyR under stress condition. 
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            Biochemical characterization of the Suf proteins from Proteobacteria 
            The SufA, SufB, SufC, SufD, SufE, and SufS proteins form the core of the Suf Fe-
S cluster biogenesis system in E. coli and related bacteria (Figure 1.4).  Although sodium 
sulfide can be used for the Fe-S cluster reconstitution in vitro, Fe-S cluster assembly 
pathways in the Proteobacteria utilize a cysteine desulfurase enzyme to mobilize sulfur 
from L-cysteine in a reaction that also requires a pyridoxal 5' - phosphate (PLP) cofactor.19, 
33-37  The cysteine desulfurase reaction produces an enzyme bound persulfide that can be 
transferred to other proteins during cluster assembly. 
            Cysteine desulfurases can be divided into group I and group II based on sequence 
analysis.38 The key difference is the structure of the active site of the desulfurase.  In the 
Suf pathway of E. coli, SufS acts as the cysteine desulfurase and is a group II desulfurase 
enzyme in which its active site residue, Cys364, is located on a rigid loop with a somewhat 
hydrophobic environment.39-41  This is in contrast to IscS and other group I enzymes that 
have a flexible catalytic cysteine loop that is exposed to the environment (Figure 1.5).42-44  
These structural differences may partially explain why the intrinsic activity of SufS is low 
compared to that of IscS.  However, SufS sometimes has a partner protein, SufE, which 
works to enhance the cysteine desulfurase activity of SufS.33, 45-47  The sufE gene can be 
found grouped with a group II cysteine desulfurase, like sufS, in Bacteriodetes and 
Gammaproteobacteria but is not wide-spread outside these phyla.10  Approximately 17% 
of the currently sequenced bacterial genomes have the sufE gene while 89% contain a sufS 
homologue. When SufE interacts with SufS, the cysteine desulfurase activity enhancement 
can be as high as 50-fold in Erwinia chrysanthemi (renamed Dickeya dadantii).33  In E. 
coli, SufE can stimulate SufS activity to 8-fold.46, 48 X-ray crystallography, enzymology,  
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Figure 1.4. Proposed model for Suf function. 
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Figure 1.5. Crystal structure of IscS (PDB code: 1P3W). The green loop is a simulated 
structure containing the active site of IscS.  
  
11 
and site-directed mutagenesis have been used to propose the overall SufS – SufE reaction 
(Figure 1.6).33, 45-51  L-cysteine binds to the PLP cofactor, which is in a hydrophobic pocket 
within the active site and forms an external aldimine.  Then Cys364 carries out a 
nucleophilic attack to extract the sulfur from cysteine, which results in the formation of the 
persulfide bonded to Cys364 (R-S-SH) and the release of L-alanine.  Next the persulfide 
of SufS is transferred to the SufE cysteine residue, Cys51, via a nucleophilic attack of 
Cys51 on the R-S-SH species.  This resets SufS Cys364 allowing the enzyme to fully 
turnover, thereby enhancing its activity.  In addition to SufE acting as a substrate in the 
overall ping-pong sulfotransferase reaction, the interaction between SufS and SufE may 
allosterically stimulate the binding of L-cysteine to PLP, the formation of the external 
aldimine, and/or the formation of later reaction intermediates in SufS that also provides 
some enhancement of SufS activity.48, 51   
            A crystal structure of the SufE monomer shows that active site Cys51 is positioned 
at the end of a loop and oriented so that the side-chain is buried from solvent exposure in 
a hydrophobic cavity (Figure 1.7).49  The relative inaccessibility of SufS and SufE active 
site Cys loops protects the resting proteins from oxidation during exposure to H2O2.  
However, SufS Cys364 and SufE Cys51 must interact to facilitate persulfide transfer.  A 
complex determined for CsdA and CsdE, two homologues of SufS and SufE respectively, 
indicates that the active site loop of the sulfur acceptor protein (CsdE) is flipped out and 
interacting with the active site cleft of the cysteine desulfurase (CsdA) when the two 
proteins bind.52  A similar conformational change in SufE has been observed by hydrogen 
– deuterium exchange mass spectrometry (HDX-MS) studies (Figure 1.8).51  Furthermore, 
the D74R mutation of SufE that increases the solvent accessibility and 
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Figure 1.6. Mechanism of the reaction of SufS and L-cysteine in the presence of SufE and 
the crystal structure of the persulfide form of SufS. 
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Figure 1.7. Crystal structure of a SufE monomer (PDB code: 1MZG). The grey part is the 
hydrophobic region. The yellow stick is the active site of SufE (Cys51). 
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Figure 1.8. Alignment of CsdE (from its complex with CsdA) with resting SufE.  Active 
site Cys residues SufE C51 and CsdE C61 are shown. 
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 dynamics of the loop containing the active site Cys51 also leads to a stronger binding 
affinity with SufS than that of the wild-type SufE.48  
            In order for multiple cycles of the sulfotransferase reaction to occur, the persulfide 
on SufE Cys51 must then be released.  In vitro this can be accomplished by the addition of 
reductants (DTT, TCEP) or by specific delivery of the persulfide to the Fe-S cluster 
scaffold.45-47, 50  It was shown that SufE specifically donates persulfide to the SufB protein, 
which is the proposed scaffold of the Suf system (see below) 53.  The transfer of sulfur from 
SufS to SufE to SufB recycles SufS and SufE to their resting states ready for another round 
of desulfurase reaction.46, 47, 53  The interaction of SufE with SufB is enhanced if SufC is 
present and has formed a complex with SufB (either as SufB2C2 or SufBC2D).46, 53   
            SufB accepts persulfide sulfur from SufE, can bind a [4Fe-4S] cluster, and can 
transfer the cluster acceptor Fe-S proteins.53-56  Based on these studies, it has been proposed 
that SufB is the scaffold for Fe-S cluster assembly in Suf pathway.  SufB is not homologous 
to the IscU scaffold of the Isc system and represents a distinct class of scaffold protein.  
The two scaffold proteins also show differences in their de novo cluster assembly steps.  
IscU can form stable a [2Fe-2S] cluster intermediate or can undergo reductive coupling of 
2 x [2Fe-2S] clusters to form a [4Fe-4S] cluster.57  In contrast SufB does not seem to 
proceed through the same semi-stable intermediates to reach a [4Fe-4S] cluster, although 
the [4Fe-4S] cluster on SufB can be converted into the [2Fe-2S] form upon air exposure.53, 
56, 58  It was also shown that the IscU [2Fe-2S] cluster is less stable than the SufB [2Fe-2S] 
cluster in the presence of hydrogen peroxide, oxygen, and iron chelators, providing a partial 
biochemical rationale for use of the Suf system under stress conditions in vivo.58  
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            SufC has a nucleotide hydrolysis domain homologous to that of the ATP-binding 
cassette (ABC) family of transporters that utilize ATP hydrolysis for transport across 
cellular membranes.18, 59-61  However, SufC is expressed as a soluble cytoplasmic protein 
and is not part of a membrane bound ABC transport system.  The exact role of SufC as an 
ATPase is still unknown, but mutations in the ATP binding site abolish the in vivo Fe-S 
cluster formation of the Suf pathway.18, 19, 55 The reason for this appears to be that the Suf 
pathway may demand the activity of SufC ATPase and SufD to efficiently acquire iron in 
vivo.55     
            Interactions among the SufB, SufC, and SufD proteins result in three stable 
complexes: SufBC2D, SufB2C2, and SufC2D2.46, 55, 59, 62-65  SufD is paralogous to SufB and 
there is considerable C-terminal sequence similarity between SufB and SufD.  This region 
of shared homology includes a C-terminal region of the overall the β-helix core as well as 
the specific C-terminal α-helices where both SufB and SufD interact with SufC.64, 65  While 
SufD is a paralogue of SufB it does not seem to function directly as a Fe-S cluster scaffold. 
SufD may assist iron entry into the SufBC2D complex in conjunction with the ATPase 
activity of SufC.55  SufBC2D also can bind one equivalent of FADH2, which raises the 
possibility that the cofactor FADH2 may serve as an electron donor to reduce ferric iron or 
persulfide during Fe-S cluster assembly on SufB.56   
            While SufB2C2, and SufC2D2 can be isolated under some conditions, SufBC2D is 
the primary complex resulting from the co-expression of the entire sufABCDSE operon in 
E. coli, which suggests that it is the most stable form of the three complexes.46, 56, 65  The 
SufB protein itself is unstable and tends to form a heterogeneous oligomer when it is 
expressed alone.53, 62, 63  SufC and SufB can interact to form SufB2C2, which is capable of 
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creating and transferring Fe-S clusters to apoproteins and is more efficient than SufBC2D 
in de novo Fe-S cluster assembly on ferredoxin in vitro using readily available iron salts as 
the iron source.53, 55, 59, 63, 66 It is possible that SufB2C2 may act as the final scaffold and 
SufBC2D may be used as a distinct step for Fe-S cluster formation before the assembly of 
the final cluster on SufB2C2.66  Although SufB2C2 can assembly Fe-S clusters in vitro using 
iron salts, labile iron is tightly controlled in vivo.  Furthermore, SufB2C2 does not appear 
to be efficient at building Fe-S clusters when expressed in vivo without SufD.55  
            Therefore, formation of SufBC2D may be specifically required for iron 
mobilization from specific donors or storage sites in the cell.  This model in consistent with 
the need for SufD to build Fe-S clusters on SufB in vivo but requires further testing to be 
validated.  One weakness in the model is that SufB2C2 has not been observed in vivo from 
native expression of the suf operon and can only be isolated if sufB and sufC are expressed 
without sufD from a plasmid construct.  The third complex, SufC2D2, is formed when sufC 
and sufD are co-expressed in the absence of sufB.63, 64  To date no functional role has been 
assigned to SufC2D2 and it has not been observed in vivo from native expression of the suf 
operon.   
            The crystal structures of SufC2D2 and SufBC2D from E. coli have been solved.64, 65  
Both structures show that the interaction of SufB or SufD remodels the ATP catalytic site 
of SufC (Figure 1.9).  Binding to SufB or SufD makes the ATP binding site of SufC more 
accessible, which could facilitate ATP binding and hydrolysis.  These structural 
observations are consistent with that fact that in Thermotoga maritima, the interaction of 
SufB with SufC can enhance the low basal ATPase activity of SufC.59 Similar effects have 
also been found when comparing the low ATPase activity of E. coli SufC with the  
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Figure 1.9. Top, overall structure of SufBC2D with Hg2+ shown as grey spheres (from PDB 
5AWG).  Bottom, zoom of the metal binding site at the SufB – SufD interface with residues 
(sticks) labeled. 
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enhanced ATPase activity observed in both SufB2C2 and SufBC2D (unpublished data from 
F. W. Outten and K. S. Thomas).  In addition to the conformational changes caused in 
SufC, it has been proposed that ATP-induced dimerization of SufC could alter the SufB 
and SufD proteins in the complex.64, 65  During ATP binding and hydrolysis SufC likely 
forms a transient head to tail dimer within the SufBC2D complex, which may induce a 
gross conformational change of SufB and SufD, leading to an exposure of Cys405 of SufB 
and Cys358 of SufD in the heterodimer interface. These two residues bind an adventitious 
Hg2+ ion in the SufBC2D structure, indicating that they may be positioned to provide partial 
ligands for iron or Fe-S cluster binding.65  His360 of SufD is also in the vicinity of the Hg2+ 
binding site near the interface of SufB and SufD.  Mutation of SufB Cys405 or SufD 
His360 led to disruption of in vivo cluster assembly (although strangely mutation of SufD 
Cys358 had no obvious effect).65  SufD is not required for SufB to bind an Fe-S cluster in 
vitro but it may provide transient ligands during iron trafficking into the cluster binding 
site in vivo or during cluster transfer to an acceptor protein. 
            The final protein in the Suf Fe-S cluster biogenesis pathway, SufA, belongs to the 
A-type carrier (ATC) family, which are proposed to deliver Fe-S clusters to apoproteins.54, 
67-73  Fe-S clusters can be reconstituted on SufA in vitro and the cluster binds to SufA 
through three conserved cysteine residues.67, 68  In vivo studies show that when SufA is co-
expressed with the whole suf operon, it purifies bound to a [2Fe-2S] cluster71 and this form 
of SufA can transfer its Fe-S cluster to both [2Fe-2S] and [4Fe-4S] apoproteins.  Elegant 
analysis of the NifIscA homologue of SufA from A. vinelandii shows the protein can 
interconvert from a [2Fe-2S] cluster form under aerobic conditions to a [4Fe-4S] form 
under anaerobic, reducing conditions.74  This cluster conversion activity could be important 
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for responding to changes in oxygen availability and/or altering the pool of available 
clusters to fit demand for specific cluster types.  In vitro, Fe-S clusters can be transferred 
from the SufBC2D scaffold to SufA while the transfer in the reverse direction does not 
occur.54  SufA physically interacts with SufB and this interaction is promoted if SufB is 
part of the SufBC2D complex and if SufBC2D is in the Fe-S cluster (holo) form.54  
Reactions containing all the components show that SufA can accept Fe-S clusters from 
SufB and move them to downstream target enzymes, supporting a role for SufA as an Fe-
S cluster trafficking protein.66, 71   
            These in vitro studies are supported by characterization of ∆sufA mutant strains in 
vivo.  The growth defect of a ∆sufA single mutant is mild but the growth defects are 
enhanced if the ∆sufA mutation is combined with deletions of iscA and/or erpA, two 
paralogues of SufA.11, 19, 20, 72, 73.  Defects in Fe-S cluster biogenesis in these strains are 
more pronounced under aerobic conditions, where cluster turnover would be expected to 
increase due to damage from reactive oxygen species, and seem to be largely confined to 
the [4Fe-4S] proteins.72, 73  Therefore it seems that the ATC family of proteins likely 
provides advantages for Fe-S cluster trafficking under aerobic conditions. 
            SufA and its paralogue IscA can also bind and donate iron in vitro for cluster 
assembly on the IscU scaffold.75-80  NifIscA from A. vinelandii binds Fe(III) in a 5-
coordinate site with two or three cysteinate ligands and can bind Fe(II) with three cysteinate 
and 1-2 oxygenic ligands in a site similar to reduced rubredoxins or rubredoxin variants.80  
The iron-donation activity of SufA and IscA may be an artifact since iron release is 
mediated by L-cysteine present during the in vitro reaction and does not appear to be a 
specific donation process directly to the scaffold.75, 77, 78, 80  While an in vivo role for 
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SufA/IscA for iron donation has not been conclusively demonstrated, it was shown that an 
IscA Y40F mutant that cannot bind mononuclear iron also cannot restore growth of the 
∆iscA∆sufA double mutant strain.70  A recent study in E. coli shows that deletion of iscA 
and sufA or addition of a cell-permeable iron chelator results in accumulation of a red 
intermediate in recombinant IscS that is being over-expressed in that strain.81  This IscS 
intermediate is likely a trapped alanine-quinonoid intermediate of the cysteine desulfurase 
reaction, suggesting that the ATC proteins are needed for the early steps of Fe-S cluster 
biogenesis to progress.81  However, it is not clear from those studies if the intermediate 
accumulates due to a downstream block in cluster release from the scaffold protein IscU to 
the ATC proteins or if it occurs due to a direct role for the ATC proteins during cluster 
assembly.  When considering all of the published studies on ATC proteins, it seems 
reasonable to hypothesize that they may have multiple functions or that their Fe-S cluster 
carrier function could be modulated by iron binding.  For example, the iron-binding activity 
of SufA and IscA may have a physiological role in regulating Fe-S cluster biogenesis in 
response to iron availability in vivo or the ATC proteins may serve as ferric iron 
“reservoirs” that can release iron into a labile pool to help indirectly drive Fe-S cluster 
biogenesis.     
            Interactions among the multi-protein Suf complexes are important for regulating 
the stepwise assembly of Fe-S clusters.  SufS relies on SufE to amplify its low basal 
activity, both by acting as a substrate as well as by allosterically influencing the SufS active 
site.  The sulfotransferase activity of the SufS – SufE pair is itself significantly increased 
in the presence of SufBC2D or SufB2C2 but not if SufB alone is added.  Similarly, the 
ATPase activity of SufC is low unless it is bound to its partner proteins, SufB and/or SufD.  
22 
Finally, SufA interactions with SufB are enhanced if SufB binds an Fe-S cluster as part of 
the SufBC2D complex.  These interactions provide tight regulation to protect sensitive 
reaction intermediates (such as enzyme-bound persulfide and/or nascent Fe-S moieties) 
from oxidative stress.  It is likely that these characteristics are biochemical adaptations that 
allow the Suf pathway to maintain Fe-S cluster biogenesis under stress.  In vitro and in vivo 
it is clear that the IscS cysteine desulfurase and IscU scaffold of the Isc pathway are more 
sensitive to inactivation by oxidants and chelators compared with the SufS-SufE-SufBC2D 
super complex.15, 50, 58 
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CHAPTER 2 
MECHANISM OF ACTIVATION OF SUFS BY SUFE: EQULIBRIUM 
AND PRE-EQUILIBRIUM KINETIC ANALYSIS 
 
ABSTRACT 
            SufS is a cysteine desulfurase to abstract sulfur from L-cysteine and provides a 
sulfur source for the Fe-S cluster biosynthesis. SufE interacts with SufS to accept sulfur 
from SufS, which turnovers SufS and enhances its activity. This interaction also induces 
allosteric changes in the structure of SufS. To investigate the effects of these changes on 
the catalytic mechanism, we applied 31P NMR, stopped flow spectra absorption, and site 
mutagenesis. The result shows that the binding of SufE causes a conformational change of 
the PLP cofactor in SufS, which may provide a better orientation for the reaction with L-
cysteine. The reaction of L-cysteine and SufS is a biphasic process including the fast phase 
(formation of external aldimine) and slow phase (formation of external ketimine). The 
binding of SufE facilitates the formation of external ketimine. We mutated the His123 of 
SufS to Ala, which removed the enhancement of SufE to the activity of SufS and the 
facilitating effect for the formation of external ketimine. Finally, the binding of SufE 
increases the formation of the persulfide in SufS. Together, these results clarify the role of
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SufE in the persulfide formation of the reaction between SufS and L-cysteine, which 
provides a clearer picture of the effect of the interaction between SufS and SufE.   
 
INTRODUCTION 
            Cysteine desulfurases are the class of enzymes that promote the abstraction of 
sulfur from L-cysteine and transfer it to the acceptor molecules for the biosynthesis of 
sulfur-containing cofactors such as thiamin, molybdenum cofactor, thionucleotides in 
tRNA, biotin, and iron-sulfur clusters1-3. All cysteine desulfurases studied so far are related 
in evolution and display similar structures that each monomer of the homodimer contains 
both the active site Cys-thiol and a PLP cofactor bound to a strictly conserved Lys residue 
via a Schiff base (internal aldimine)4. Cysteine desulfurases can be divided into group I 
and group II based on sequence analysis and the key difference is the structure of the active 
site4. SufS acts as the cysteine desulfurase in the Suf pathway of E. coli, which produces 
Fe-S clusters under oxidative stress and iron starvation conditions5. SufS is a group II 
desulfurase enzyme and Cys364, its active site residue, locates on a rigid loop with a 
hydrophobic environment while IscS and other group I desulfurases have a flexible 
catalytic cysteine loop exposed to the environment, which may be one part of the reason 
why the basal activity of IscS is much higher than SufS6-8. SufS has a specific sulfur 
acceptor SufE whose coding gene sufE is adjacent to sufS. SufE interacts with SufS to 
accept the sulfide from SufS. It activates SufS to enhance its activity to a level comparable 
to IscS. And SufS-SufE sulfur transfer system is more resistant to oxidative stress than 
IscS9. However, the catalytic mechanisms of the effects of SufE on SufS except accepting 
sulfur are not completely clear.  
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            Enzymology, site-directed mutagenesis, ITC, X-ray crystallography and so on have 
been used to clarify the reaction of L-cysteine and SufS in the presence of SufE9-12. L-
cysteine is activated by binding to the PLP cofactor before the C-S bond of L-cysteine is 
cleaved by a nucleophilic attack from the active site Cys364 residue, which results in the 
formation of a persulfide at the active site (Cys364-S-SH)10. SufE binds to SufS to accept 
the sulfide. It allows SufS to fully turn over, consequently enhancing its activity9. Also, the 
binding of SufE initiates allosteric changes in the SufS structure including the peptide 
containing the conserved Lys residue that forms the Schiff base with the PLP cofactor. This 
allosteric change facilitates the binding of L-cysteine to the enzyme to form external 
aldimine or other reaction intermediate11. This finding leads us to investigate the role of 
SufE in enhancing the activity of SufS beyond accepting sulfide from SufS. 
            In this study, we reported that the effects of the binding of SufE on the PLP 
conformation, the pre-steady-state and steady-state kinetics of the reactions between SufS 
and L-cysteine in the presence or absence of SufE in a one turnover model, and the role of 
the binding of SufE on the persulfide formation. The results show that the interaction 
between SufE and SufS can cause a conformational change of the PLP cofactor in SufS, 
which may provide an appropriate orientation for its reaction with L-cysteine. The reaction 
of L-cysteine and SufS is a biphasic process including the fast phase (the pre-steady state) 
and slow phase (the steady state). External aldimine is produced in the fast phase and 
external ketimine is produced in the steady state. The binding of SufE facilitates the 
formation of external ketimine. Also, we used site-directed mutagenesis to investigate the 
possible catalytic mechanism of the effects of the SufE binding. Our result suggests His123 
of SufS plays an important role in the reaction of SufS and L-cysteine in the presence of 
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SufE. The mutant SufS H123A cannot be enhanced by SufE in the desulfurase reaction. 
Also SufE cannot facilitate the formation of external aldimine in SufS H123A. Finally, we 
investigated the formation of persulfide in SufS and found that the binding of SufE 
enhances the formation of persulfide. Together with the finding that SufE binding induces 
allosteric changes in SufS, the present results demonstrate that SufE activates SufS by both 
accepting sulfur as well as by promoting the first step of the ping-pong reaction.  
 
MATERIALS AND METHODS 
Strains, Plasmids and Site-mutagenesis 
SufS, SufS H123A, SufS C364A, SufE, and SufE C51A were expressed in 
BL21(DE3). The expression plasmids are constructed in the following steps. We used 
MG1655 chromosomal DNA as the template for PCR. The fragment of sufS was digested 
with XhoI and BamHI. After the digestion, the sufS fragment was ligated into the 
corresponding sites of the plasmid pET-21a (Invitrogen) to generate pET-21a_sufS. The 
fragment of sufE was digested with BamHI and NdeI. Then it was cloned into the 
corresponding site of pET-21a to make pET-21a_sufE.  
The SufS H123A, SufS C364A used pET-21a_sufS as the template. The SufE C51A 
used pET-21a_sufE as the template. The substitution was introduced by the site-directed 
mutagenesis using the QuikChange kit (Stratagene). All the primer sequences are described 
in Table 2.1. 
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Protein expression and purification 
E. coli BL21(DE3) containing pET-21a_sufS, pET-21a_sufS H123A or pET-
21a_sufS C364A was grown in LB with 100 µg/mL ampicillin at 37 ˚C for overnight, 
diluted by 100 fold into LB, incubated with shaking to reach an OD600 of 0.4 – 0.6 before 
induced by 500 µM IPTG at 18 ˚C overnight. Cells were harvested and lysed in 25 mM 
Tris-HCl, pH 8.0, 5 mM DTT, and 1 mM PMSF via sonication. After centrifugation at 
14000 rpm for 30min, the lysate was loaded on the columns. The WT SufS or the SufS 
mutants were purified through Q-sepharose, phenyl and Superdex 200 chromatography 
resins in sequence. The Q-sepharose column used a linear gradient from 25 mM Tris-HCl, 
pH 8.0, 10 mM βME to 25 mM Tris-HCl, pH 8.0, 1 M NaCl, 10 mM βME. The phenyl 
column utilized a linear gradient from 25 mM Tris-HCl, pH 8.0, 100mM NaCl, 1M 
ammonium sulfate, 10 mM βME to 25 mM Tris-HCl, pH 8.0, 10 mM βME. The Superdex 
column run with 25mM Tris-HCl, pH 8.0, 150mM NaCl, 10 mM βME. Purified proteins 
were concentrated, frozen as drops in liquid nitrogen, and stored at – 80 ˚C degrees until 
further use. 
E. coli BL21(DE3) containing pET-21a_sufE or pET-21a_sufE C51A was grown 
in LB with 100 µg/ml ampicillin at 37 ˚ C for overnight, diluted 100 fold into LB, incubated 
with shaking to reach an OD600 of 0.4 – 0.6 before induced by 500 µM IPTG at 37 ˚C for 
3 hours. Cells were harvested and lysed in 25mM Tris-HCl, pH 8.0, 5mM DTT, and 1 mM 
PMSF via sonication. After centrifugation at 14000 rpm for 30min, the lysate was loaded 
on the columns. The WT SufE or SufE C51A was purified through Q-sepharose and 
Superdex 200 chromatography resins in sequence. The Q-sepharose column used a linear  
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Table 2.1 Primer sequences for plasmid construction of pET21a_sufS, pET21a_sufE9 and 
site-directed mutagenesis for construction of pET21a_SufS H123A, pET21a_SufS C364A, 
pET21a_SufE C51A  
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gradient from 25 mM Tris-HCl, pH 8.0, 10 mM βME to 25 mM Tris-HCl, pH 8.0, 1 M 
NaCl, 10 mM βME. The Superdex column run with 25mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 10 mM βME. Purified proteins were concentrated, frozen as drops in liquid nitrogen, 
and stored at – 80 Celsius degrees until further use. 
 
31P NMR Spectroscopy 
Fourier-transform 31P NMR spectra was collected at 121.497 MHz on a Bruker 400 
MHz super wide-bore superconducting spectrometer using a 5-mm multinuclear probehead 
with broadband 1H decoupling. The NMR tube contained the sample (2 mL) and 2H2O (0.2 
mL) as field/frequency lock and was maintained at 15 Celsius degrees using a thermostated 
continuous air flow. The protein concentration was 1 mM subunits. A spectral width of 
2000 Hz was acquired in 8K data points with a pulse angle of 60 degrees. The exponential 
line broadening used prior to Fourier transformation was 10 Hz. The acquisition times were 
in the range of 1 to 15 hour with a repetition time of 2 s. Positive chemical shifts in ppm 
are downfield changes with respect to 85% H3PO4. Monoprotic titiration curves were 
calculated by least squares analysis. 
 
Cysteine Binding Assays 
All assays were conduct at room temperature in 25 mM Tris-HCl, pH 7.4, 150 mM 
NaCl. The binding between SufS and L-cysteine was evaluated by monitoring the 
immediate ΔA340 elicited by the addition of increasing concentrations of L-cysteine to 25 
µM WT SufS or 25 uM WT SufS with an equal amount of SufE C51A using a BECKMAN 
COULTER DU 800 spectrophotometer. Protein and L-cysteine were added into the 
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cuvettes and mixed for around 5 s before the wavelength scan from 200 to 650 nm. Data 
were analyzed with the GraphPad Prism software. ΔA340 was best fit with the one-site-
specific binding model. 
 
Stopped-flow Absorption Spectroscopic Analysis 
Stopped-flow absorption experiments were performed on an Applied Photophysics 
Ltd. SX20 stopped-flow spectrophotometer. 25 µM WT SufS or 25 µM WT SufS with an 
equal amount of SufE C51A or 25 µM SufS H123A with an equal amount of SufE C51A 
was rapidly mixed with increased concentration of L-cysteine. The reaction was performed 
in the buffer 25 mM Tris-HCl, pH 7.4, 150 mM NaCl. Single wavelength traces were taken 
by a photomultiplier tube. Full spectrum data were collected by photodiode array. The 
single wavelength data at 370 nm were best fit to the double exponential model using Pro 
Data Viewer version 4.2.18.  
 
Cysteine Desulfurase Activity Assay 
Cysteine desulfurase activity was measured through the formation of methylene 
blue with NNDP and FeCl3 using the protocol below. Reactions were conduct aerobically 
in 25mM Tris-HCl, pH 7.4, 150 mM NaCl at room temperature. 0.5 µM SufS or SufS 
mutants and 2 µM SufE were incubated in the buffer for 5 min before the addition of 2mM 
L-cysteine and 2mM DTT. The total volume of the reaction system was 800 µL. Reactions 
proceeded for 10 min and were quenched by adding 100 µL 20mM NNDP in 7.2 M HCl 
and 100 µL 30 mM FeCl3 in 1.2 M HCl. The mixture was incubated in the dark for 30 min 
to produce methylene blue. Precipitated protein was removed by 1 min centrifugation at  
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13000 rpm and the methylene blue was measured at 670 nm. A Na2S standard line was 
made for calibration of the content of sulfur product from this reaction. 
 
Identification of the SufS-Bound Persulfide 
The SufS-bound persulfide was identified using a slightly modified published 
protocol. 50 nmol SufS or SufS mutants was incubated with 400 nmol L-cysteine in 25 
mM Tris-HCl, pH 8.0, 150 mM NaCl for 20s before 300 nmol of 1,5-I-AEDANS was 
added. The reaction proceeded for 30 min. Then the excess of the 1,5-I-AEDANS was 
removed by washing three times with the above buffer using the centrifugal filter (Amicon 
Ultra - 15). The samples were brought to 1 mL with the buffer and then equally divided to 
500 uL. An aliquot of 1 M DTT (55.6 µL) was added to one sample (500 µL) to give a 
final concentration of 5 mM to reduce any formed persulfide (disulfide bond) from SufS 
and the fluorescent compound. The other half was not reduced by DTT and served as a 
control. The incubation time with DTT was 30 min. Then, small molecules were separated 
from protein by washing three times with the above buffer by using the centrifugal filter. 
Finally, all the samples were brought to 500 µL with the buffer and the relative persulfide 
percentage was determined spectrofluorometrically with the BioTek Synergy H1 Hybrid 
Reader. The λex was 336 nm and the λem was 490 nm.  
 
RESULTS 
Binding of SufE changes the conformation of PLP in SufS 
Our former research proved that the binding of SufE to SufS leads to 
conformational changes within the peptide of SufS including the Lys226 that forms a Schiff 
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base with the PLP cofactor11. Thus it is reasonable to hypothesize the binding of SufE 
changes the conformation of the PLP cofactor of SufS. To further test if the binding of 
SufE can cause a conformational change of PLP, 31P NMR spectroscopy was applied. The 
31P NMR allows monitoring of the microenvironment around the 5’-phosphate group of 
the enzyme-bound PLP by detecting its chemical shift under different conditions (Figure 
2.1). It is acquired with 1H decoupling, which produces a single resonance line for the 31P 
nucleus of PLP. If the line width of the single resonance is narrow, then this indicates that 
there is free rotation around the C5’-O4’ bond of the phosphate group. Alternatively, 
observing an increased line width suggests this rotation is restricted. A typical 31P NMR 
spectrum analysis includes matching the expected chemical shifts to the expected moieties. 
Each type of signal has a characteristic chemical shift range. Important factors influencing 
chemical shift include the electron density and electronegativity of neighboring groups. 
The decreasing of the electron density can cause a downfield shift in the NMR spectrum.    
For SufS alone, there are two 31P NMR signals at 3.4 ppm (60%) and 2.4 ppm 
(40%). The presence of SufE shifts the 31P NMR signals to 3.3 ppm (95%) with a small 
portion (5%) still present at 2.4 ppm (Figure 2.2). In both the absence and presence of SufE, 
line widths are consistent with restricted rotation about the C5’-O bond linking the 
phosphate ester to the pyridine moiety of the cofactor. This result indicates that the binding 
of SufE changes the microenvironment of the phosphorus in the cofactor PLP, possibly to 
obtain the proper conformation for the reaction of the PLP cofactor and the substrate L-
cysteine.    
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Figure 2.1. Chemical shift of phosphorus-containing group and PLP. PLP is one type of 
orthophosphate monoesters whose chemical shift is between 2 ppm – 6 ppm19. 
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Figure 2.2. 31P NMR spectra of SufS in the absence and presence of SufE. (A) 31P NMR 
spectrum of 500 µM SufS in 25 mM Tris-HCl, 50 mM NaCl buffer, pH 8.0. (B) 31P NMR 
spectrum of 500 µM SufS and 500 µM SufE in 25 mM Tris-HCl, 50 mM NaCl buffer, 
pH 8.0. The signal at 4.5 ppm is considered to be an impurity containing phosphorus 
from protein purification.  
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Kinetics of Reaction of SufS with L-Cysteine with/without SufE C51A 
In the study of the L-cysteine binding to SufS, we already showed that the presence 
of SufE facilitates the formation of a L-cysteine-SufS PLP intermediate(s) with an 
absorption maximum at 340 nm under the steady state11. Here stopped-flow experiments 
were applied to investigate the kinetics of the binding of L-cysteine to SufS under the pre-
steady state and the effects of SufE in this reaction. The stopped-flow experiment is to use 
a rapid mixing device to study the chemical kinetics of the fast reaction. The half-lives of 
the fastest reaction that the stopped-flow instrument can study can be as short as a few 
milliseconds. In a stopped flow experiment (Figure 2.3), the substrates and enzymes are 
forced from two separated syringes into a mixing chamber. After a very short period of 
flow, the flow is stopped and the mixture is observed by the monitoring probe. The dead 
time is the period between the end of mixing and the beginning of the observation of the 
kinetics for the reaction, which is usually 1-2 ms.  
 The active site of SufE, Cys 51, was mutated to Ala (SufE C51A), which prevents 
the sulfur transfer from SufS to SufE and blocks SufE enhancement of SufS turnover 
(Figure 2.4). However, SufE C51 still binds to SufS thus allowing us to exclusively 
investigate the effect of SufE binding on the initial reaction of L-cysteine and SufS to form 
a SufS-persulfide intermediate.  We observe that SufE C51A can still facilitate the 
formation of the intermediate(s) at 340 nm under the steady state similar to what we 
observed previously for SufE (Figure 2.5). 
Interrogation of the reaction of SufS with L-cysteine by the stopped-flow 
absorption spectrophotometry revealed the decay of internal aldimine at 420 nm and the  
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Figure 2.3. Model of a stopped-flow device. 
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Figure 2.4. Comparison of the activities of WT SufS with WT SufE/SufE C51A. 0.5 µM 
SufS reacts with 2 µM WT SufS or 2 µM SufE C51A. 
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Figure 2.5. Formation of intermediate(s) upon addition of L-cysteine to SufS in the 
absence and presence of SufE C51A. (A) Percentage of change at 340 nm after adding 
increasing concentration of L-cysteine to 25 µM SufS. The solid line is fit of one-site 
binding model and corresponds to a Kd value of 35 ± 8 µM. (B) Percentage of change at 
340 nm after adding increasing concentration of L-cysteine to 25 µM SufS and 25 µM 
SufE C51A. The solid line is fit of one-site binding model and corresponds to a Kd value 
of 7 ± 1 µM.  
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accumulation of an intermediate(s) at 340 nm (Figure 2.6). Fitting the time course for the 
intermediate(s) at 340 nm using regression methods required a double exponential (two 
phase association) model with observed rate constants (kobs) k1 = 7.35 ± 0.12 s-1 and k2 = 
0.16 ± 0.0044 s-1 (Figure 2.7). The complex biphasic kinetic behavior for the formation of 
the intermediate(s) at 340 nm may be attributed to multiple populations of one intermediate 
reacting at different rates, or may alternatively occur because there are two different 
intermediates that both absorb at the same wavelength (340 nm). 
Based on the accepted mechanism of the reaction between cysteine desulfurase and 
L-cysteine13,14(Figure 2.8), a PLP transsulfuration begins when the internal aldimine that 
absorbs at 420 nm shifts to the external aldimine Schiff base that absorbs at 340 nm. Then 
the α proton of the substrate is abstracted by an enzyme residue serving as a general base 
to form the external ketimine via a transient intermediate Cys-PLP quinonoid. It is 
postulated that during our single-turnover reaction we observe the accumulation of both 
the external aldimine and the external ketamine intermediates, which forms a mixture in 
equilibrium at 340 nm.  
To test if two intermediates may be present, singular value decomposition (SVD) 
was applied to the complex photodiode array (PDA) data. SVD is a mathematical method 
which is a factorization of a complex matix. It can decompose a normal matrix to any m * 
n matrix via an extension of polar decomposition. We utilized SVD to decompose the 
matrix of the PDA data where the number of singular values (number of the decomposed 
matrixes) equals the number of intermediates in this stopped-flow experiment. In our 
experiment, three singular values were obtained, which represents three species in this 
reaction (Figure 2.9). Using global analysis methods, the pure optical spectra for external 
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Figure 2.6. Stopped-flow absorption spectrophotometry of SufS and L-cysteine. PDA 
spectrum of a single turnover reaction of 25 µM SufS and 1 M L-cysteine. 
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Figure 2.7. Representative single-wavelength (340 nm) time course for the reaction of 25 
µM SufS and 1M L-cysteine. The red line represents the double exponential fits to the 
data. 
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Figure 2.8. Proposed mechanism of the desulfurase reaction between SufS and L-cysteine. 
External aldimine is obtained through a transimination reaction. After deprotonation, 
external ketimine was formed before the persulfide formation.  
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Figure 2.9. SVD basis vectors after SVD calculation for the PDA data of the reaction 
between 25 µM SufS and 1 M L-cysteine. S1 – S4 are the singular values. S4 is much 
smaller than the rest of singular values, which is considered to be noise.  
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aldimine and a species we assign as the external ketimine were extracted (Figure 2.10). 
Both the pure external aldimine and the pure external ketamine have similar absorption 
features around 340 nm.  Based on the observed rate constants in the fast phase and slow 
phase, we computed the three intermediates in the reaction of SufS and L-cysteine (Figure 
2.11). The pure optical spectrum at 364 nm showed two phases together: the first one is for 
the absorbance decreasing from decomposition of the internal aldimine to external 
aldimine; the second phase is going up from external aldimine to an intermediate that we 
assign as the external ketimine (Figure 2.12). It is consistent with the spectrum of the time 
course at 364 nm from the PDA data (Figure. 2.13), which further supports that external 
aldimine and external ketimine may exist as a mixture at 340 nm.  
            To delineate the kinetics of this whole reaction from internal aldimine to external 
ketimine, the dependence of both kobs in the fast and slow phases at various L-cysteine 
concentrations was examined in either the absence or presence of SufE C51A. The kobs of 
the fast phase shows a linear dependence on L-cysteine concentration with or without SufE 
C51A. In the absence of SufE C51A, the forward and reverse rate constants for the 
formation of external aldimine are provided by the slope (k1 = 0.012 µM-1s-1) and the 
intercept (k-1 = 0.46 s-1), which gives an equilibrium dissociation constant KD = 37.6 µM 
(k-1/ k1).  This value is lower than that measured in the presence of SufE C51A where k1 = 
0.0055 µM-1s-1, k-1 = 0.45 s-1, and KD = 82.9 µM (Figure 2.14). The kinetics indicate that 
SufE does not enhance the formation of external aldimine in the fast phase. The kobs of the 
slow phase shows a hyperbolic dependence on L-cysteine concentration regardless of the 
presence of SufE C51A. Results from the hyperbolic fit of the L-cysteine concentration 
dependence show that the y intercept of the plot is zero, which corresponds to the reverse  
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Figure 2.10. Pure components of spectra of internal aldimine (red), external aldimine 
(blue), and external ketimine (green) obtained from global fitting analysis of PDA data. 
The internal aldimine has a minimal absorption at 340 nm due to the dead time of the 
stopped-flow experiment. 
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Figure 2.11: Speciation plots of the fractional concentrations of intermediates computed 
using the rate constants determined in the PDA study of 25 µM SufS and 1 M L-cysteine. 
Internal aldimine is red, the external aldimine is blue, and external ketimine is green. 
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Figure 2.12. The spectrum at 364 nm in the pure components of spectra of internal 
aldimine (red), external aldimine (blue), and external ketimine (green). The absorption of 
internal aldimine decreases due to the formation of external aldimine and increases due to 
the formation of external ketimine.  
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Figure 2.13. The single-wavelength time course for the reaction of decay of internal 
aldimine to external aldimine and formation of external ketimine monitored at 364 nm.  
  
55 
 
 
 
Figure 2.14. Kinetic analysis of the formation of external aldimine at 340 nm at the fast 
phase (pre-equilibrium state). (A) kobs of the fast phase for 25 µM WT SufS alone following 
increasing concentrations of L-cysteine. (B) kobs of the fast phase for 25 µM WT SufS and 
25 µM SufE C51A following increasing concentrations of L-cysteine.  
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rate constant for the formation step of the second intermediate, which we assign as the 
ketimine formed from L-cysteine (k-2 = 0). The asymptote of the plot was used to obtain 
the formation rate constant for this putative Cys ketimine.  We found that k2 = 0.5111 s-1 
in the absence of SufE C51A  giving a KD = 82.94 µM.  In contrast, when SufE C51A was 
present the k2 = 0.24 s-1 resulting in a KD = 22.02 µM (Figure 2.15). These results from the 
kinetic analysis of the slow phase indicate that the formation of the second intermediate, 
which we assign as the external ketimine, is an irreversible step which is enhanced 4-fold 
by SufE C51A.  
 
His123 of SufS plays a critical role in the promotion of SufE to the formation of 
external ketimine 
According to the accepted mechanism of the reaction between cysteine desulfurase 
and L-cysteine, an enzyme residue serving as a general base is used to abstract a proton 
from the α carbon of the external aldimine, which is critical for the conversion from 
external aldimine to Cys ketimine14.  If SufE enhances this step of the desulfurase reaction 
in SufS, then SufE enhancement should be blocked by mutation of the catalytic base in 
SufS.  His123 is a conserved His residue located between the PLP cofactor and the active 
site of SufS (Figure 2.16), suggesting its potential role as a general base during the 
abstraction of the substrate α proton14. To test this hypothesis, we mutated His123 to Ala 
(SufS H123A) and analyzed the desulfurase reaction in the mutant SufS. The desulfurase 
assay showed that SufE can no longer enhance the SufS H123A activity compared with 
WT SufS (Figure 2.17). However, this mutant still kept the basal activity (1.41 mU/mg) 
which is similar as SufS alone (1.30 mU/mg). Stopped-flow spectroscopy of SufS H123A 
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Figure 2.15. Kinetic analysis of the formation of external ketimine at 340 nm at the slow 
phase (equilibrium state). (A) kobs of the slow phase for 25 µM WT SufS alone following 
increasing concentrations of L-cysteine. (B) kobs of the slow phase for 25 µM WT SufS and 
25 µM SufE C51A following increasing concentrations of L-cysteine.  
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Figure 2.16. The location of His123 in the active site of SufS. 
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Figure 2.17. Comparison of the activity of 0.5 µM WT SufS and 0.5 µM SufS H123A in 
the presence of 2 µM WT SufE. 
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and L-cysteine with or without SufE C51A also showed a biphasic process. The fast phase 
was similar as the WT SufS indicating that H123A does not interfere with formation of the 
external aldimine between L-cysteine and SufS PLP. The slow phase still had a hyperbolic 
fit, but the k2 = 0.5789 s-1 and KD = 330.7 µM in the presence of SufE C51A, which is 
much larger than WT SufS with SufE C51A (KD = 22.02 µM) (Figure 2.18). The slow 
phase of SufS H123A alone shows k2 = 0.6642 and KD = 225.5 µM, which is similar as 
SufS H123A in the presence of SufE C51A, indicating that SufE cannot enhance the 
formation of external ketimine in SufS H123A. This result indicates that His123 is required 
for SufE to facilitate formation of the external ketimine and that this activity of SufE in the 
first half of the desulfurase ping-pong reaction is a key part of SufE enhancement of SufS. 
 
SufE enhances the formation of persulfide 
According to the proposed mechanism of SufS as a desulfurase, L-cysteine can 
form a cysteine PLP adduct with the SufS cofactor PLP. The active site Cys364 thiolate of 
SufS starts a nucleophilic attack on this adduct to make remove sulfur from L-cysteine. A 
persulfide is formed on the active site Cys364 as an intermediate in this reaction10. The 
presence of SufE enhances the desulfurase activity of SufS in part by transferring the 
persulfide sulfur from the SufS Cys364 to SufBCD15. If SufE does enhance the formation 
of the ketimine intermediate in SufS as we propose here, then the presence of SufE should 
also enhance persulfide formation on SufS Cys364, which is stable enzyme intermediate 
formed upon completion of the first half of the ping-pong desulfurase reaction.  To test if 
SufE can facilitate the formation of persulfide of SufS, we used SufE C51A, which still 
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Figure 2.18. Kinetic analysis of the formation of intermediates at 340 nm from SufS H123A 
and L-cysteine in the presence of SufE C51A. (A) kobs of the fast phase for 25 µM SufS 
H123A and 25 µM SufE C51A following increasing concentrations of L-cysteine. (B) kobs 
of the slow phase for 25 µM SufS H123A and 25 µM SufE C51A following increasing 
concentrations of L-cysteine. 
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interacts with SufS but cannot remove persulfide from SufS, thus we are only analyzing 
the effect of SufE on that first half of the reaction.  After mixing L-cysteine and SufS with 
or with SufE C51A, the fluorescent alkylating reagent 1,5-I-AEDANS was added to 
alkylate exposed thiol or persulfide sulfurs.  Excess IAEDANS was removed by extensive 
washing.  If there is no persulfide present a stable thioether derivative will be formed 
between IAEDANS and residues such as Cys364, which cannot not be broken using the 
reductant DTT13 (Figure 2.19).  However, if IAEDANS alkylates an enzyme-bound 
persulfide at Cys364 then the addition of DTT will reduce the persulfide and release the 
IAEDANS, resulting in a loss of fluorescent signal from the IAEDANS.  We also mutated 
the active site of SufS from Cys to Ala (SufS C364A) and alkylated this mutant mixed with 
SufE C51A with IAEDANS to measure the background alkylation signal from the other 3 
Cys residues in SufS and the one additional Cys residue in SufE C51A (none of which are 
directly involved in the desulfurase reaction). The results showed that the reaction of 1,5-
I-AEDANS with a mixture containing SufS, SufE C51A, and L-cysteine results in the 
formation of a DTT-reducible persulfide species at the active site of SufS in 91.1% of the 
enzyme (compared with the control with SufS C364A and SufE C51A). If SufE C51A is 
omitted from the reaction, the DTT-reducible persulfide formation at the SufS active site 
of this enzyme is decreased to 62.4% (Figure 2.20). We extended the reaction time from 
20s to 3 min and this percentage remained the same in both presence and absence of SufE 
C51A, which means an equilibrium was formed. Without the treatment with DTT, the total 
fluorescence signals of the SufS with/without SufE C51A were similar to each other. These 
results indicate that the presence of SufE facilitates the formation of persulfide in the early 
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Figure 2.19. Scheme for the identification of a SufS-bound persulfide.  
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Figure 2.20. Fluorescence spectrum of SufS and L-cys with/without SufE C51A. SufS 
reacted with L-cys with/without SufE C51A. The samples incubated with 1,5-I-AEDANS. 
Then they were treated with/without DTT. 1,5-I-AEDNAS can react with cysteine residue 
to form a sulfide derivative which cannot be released by DTT. It can also react with 
persulfide to form a persulfide derivative which can be released by DTT. SufS C364A has 
no persulfide formation because the active site is mutated, which reacts with L-cysteine to 
provide the blank control. 
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steps of the reaction between SufS and L-cysteine even if SufE is not competent to remove 
the persulfide from SufS due to the C51A mutation.  
 
DISCUSSION 
            It has been proven that SufE enhances the activity of SufS by removing the Cys364 
persulfide to make it turnover9. We have previously shown that the binding of SufE 
initiated allosteric change in SufS including the peptide containing the conserved Lys 
residue that forms Shiff base with the PLP cofactor, which facilitates the binding of L-
cysteine to the PLP cofactor11. Our current hypothesis is that binding of SufE can also 
promote the formation of an enzyme-bound persulfide by facilitating the production of 
intermediates in the reaction between SufS and L-cysteine. In the present study, we proved 
that the binding of SufE causes conformational change of the PLP cofactor through 31P 
NMR, which may provide a more favored orientation of the PLP to react with L-cysteine. 
To elaborate the influence of the SufE binding to the reaction mechanism, we applied 
stopped-flow experiment to study the pre-steady state. We showed a model that describes 
the proposed mechanism for the reaction of SufS and L-cysteine and proved that the 
presence of SufE facilitates the formation of an intermediate beyond the external aldimine 
which we assign as the Cys ketimine. To further clarify this mechanism, we mutated the 
His123 to Ala in SufS. This mutation blocked the enhancement of SufS by SufE, which 
demonstrated that His123 plays an important role in the catalytic mechanism.  Finally, we 
observed that the binding of SufE C51A increases the formation of the persulfide in SufS, 
which is consistent with our hypothesis. 
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            To our knowledge the pre-steady-state kinetics of the group II cysteine desulfurase 
like SufS and L-cysteine with/without SufE is not described previously. The result 
demonstrates biphasic kinetics in the accumulation of the intermediate(s) at 340 nm. The 
SVD calculation shows 3 singular values that implies three intermediates in the whole 
reaction16. Taken together, there may be two intermediates in the growing absorption at 
340 nm. Traditionally, external aldimine of cysteine is believed to absorb at 340 nm 
according to spectral change and the accepted reaction mechanism of cysteine desulfurase. 
In our former kinetic research under the steady state, we indicate that external aldimine of 
L-cysteine is absorbed at 340 nm. However, in the kinetic analysis in the cysteine 
desulfurase CD 0387 from Synechocystis sp. PCC 6803, Cys ketimine is proved to exist at 
340 nm at the steady state by the deuterium equilibrium isotope effect17. Here we show that 
the accumulation of external Cys aldimine is fast, which gives rise to the initial observable 
fast phase of the reaction at 340 nm.  However, the reaction that produces Cys ketimine 
produces a slow phase at 340 nm at the steady state. The structures of external aldimine 
and ketimine are very similar except the position of the double bond, which may explain 
the similarity of their spectral absorption. The quinonoid (506nm) in the reaction 
mechanism is observed in the group I cysteine desulfurase17,18.  However, we do not 
observe a quinonoid intermediate between the aldimine and ketimine in the stopped flow 
experiments with SufS and L-cysteine regardless of the presence of SufE. The reason may 
be due to the difference in the structures of group I and group II cysteine desulfurases that 
group I cysteine desulfurase may better stabilize the short-lived quinonoid intermediate.    
            Catalytic activity of many enzymes is sensitive to conformational dynamics that 
can be influenced by allosteric regulation. Previously we demonstrated the binding of SufE 
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caused highly localized dynamic perturbations within residues 225-236 (including the Lys 
binding to PLP) and 356-366 (the loop including the active site Cys364)11. Since residues 
225-236 locates deeply in the active site cavity, its conformational change around PLP 
upon SufE binding may be transmitted via the 356-366 loop with the active site. Here our 
data provides direct evidence to the allosteric change of the PLP cofactor in SufS upon 
SufE binding. The pre-steady-state kinetic research demonstrates that the SufE binding 
actually facilitates the formation of Cys ketimine that is the intermediate after the formation 
of external Cys aldimine. The external Cys aldimine in SufS seems to have a similar 
absorbance as the Cys ketimine, such that they are not easily distinguished in a steady-state 
experiment and were observable here using SVD analysis of pre-steady state data. We also 
demonstrate the critical role of His123 in the reaction mechanism. It is possible that the 
SufE binding shifts the PLP cofactor to an optimal orientation that facilitates the general 
base, His123, to abstract the α proton from the external Cys aldimine, which shifts the SufS 
active site equilibrium toward the formation of Cys ketimine. The finding that SufE 
increases the persulfide formation supports this theory since shifting the reaction forward 
to the ketimine should promote formation of the final persulfide product. 
            In summary, we clarified the role of the SufE binding in persulfide formation of the 
reaction of SufS and L-cysteine. The observed changes in the PLP conformation and pre-
steady-state kinetics suggest that SufE actively promotes the Cys ketimine formation. The 
site directed mutagenesis proves that His123 plays an important role in the process above, 
likely by acting as a catalytic base. Finally, the changes SufE binding induces increase the 
persulfide formation. Based on our former research, this study further elucidates the 
catalytic mechanism of SufS as cysteine desulfurase and the role of SufE in both persulfide 
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formation and sulfur transfer, which provides a clearer picture of the interaction between 
SufS and SufE.   
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CHAPTER 3 
CHARACTERIZATION OF THE INTERACTION INTERFACE OF SUFS 
AND SUFE 
 
ABSTRACT 
            Fe-S clusters are one major type of the sulfur-containing cofactors, which conduct 
essential functions in organisms. SufS is a cysteine desulfurase that provides sulfur for the 
formation of Fe-S cluster. It is the beginning of the Suf pathway, which forms Fe-S clusters 
for E. coli under iron limitation and oxidative stress. The basal activity of SufS is quite low 
and it needs the interaction of SufE for activation. The interaction of SufE is essential for 
the normal activity of SufS. The study on the interaction of SufS and SufE may lead to a 
design of protein-protein interaction inhibitors to disturb the binding of SufE to SufS, 
which may shut down Suf pathway with a potential of a new type of antibiotic. We 
generated the Y345A/D346A mutations in SufS and applied PLP quantification, analytical 
gel filtration, UV-visible spectroscopic analysis and circular dichroism to confirm this 
mutant still keeps the structural integrity. The basal activity of SufS Y345A/D346A is 
similar as that of WT SufS but SufE cannot enhance the activity of this mutant. The results 
of ITC show that there is no more interaction between this mutant and SufE. SufS residues 
Ser262 and Glu263 are other candidates for the interaction with SufE. However, the
72 
S262A/E263A mutations on SufS do not alter enhancement by SufE. Based on the research 
above, a structural modeling of the SufS-SufE interaction was made through protein-
protein docking, which clarifies more details in this interaction.   
 
INTRODUCTION 
            Sulfur containing cofactors are essential in many biochemical reactions and 
distributed widely in nature. Fe-S clusters are one major type of the sulfur-containing 
cofactors, which are made up of Fe2+ or Fe3+ bounded to sulfides that bridge the iron ions. 
They coordinate to proteins through cysteine residues. [4Fe - 4S] is the most abundant type 
in metalloproteins. They are stable at multiple oxidation states with physiologically 
relevant redox potentials. Fe-S clusters perform important functions in cells such as 
substrate binding and catalysis, electron transfer, sensing reactive oxygen and nitrogen 
species, genetic regulation in transcription and translation1,2. The biogenesis of Fe-S 
clusters in vivo is undertaken by a series of proteins working cooperatively and the core 
steps include sulfur mobilization, iron donation, assembly of Fe-S clusters on a scaffold 
protein, and Fe-S cluster trafficking from scaffold protein to target proteins1. These core 
steps form a framework for Fe-S cluster formation, which is universal in various organisms. 
Currently three main Fe-S cluster assembly systems are identified in bacteria including the 
isc, nif and suf pathways3,4. The nif pathway assemblies Fe-S clusters in the nitrogenase 
enzymes. The isc pathway is found in both procaryotic cells and the mitochondria of 
eukaryotic cells to generate various Fe-S clusters for metalloproteins. The suf pathway is 
present in many gram-negative and the plant chloroplast. In some bacteria, suf pathway can 
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undertake the biogenesis of Fe-S clusters under oxidative stress and iron limitation5. E. coli 
has both isc and suf pathways for the Fe-S cluster assembly6. All of the three pathways 
utilize cystine desulfurase like NifS, IscS, and SufS individually to abstract sulfur from L-
cysteine. Then the sulfur is transferred to the scaffold protein where nascent Fe-s clusters 
are assembled after iron donation7. NifU and IscU act as the scaffold proteins in the nif and 
isc pathways. SufU is homologous to IscU, which can form [4Fe - 4S]2+ clusters in B. 
Subtilis8. In E. coli, SufBC2D replaces SufS to act as the scaffold protein in suf pathway9.   
            E. coli is the model organism we use to investigate the mechanism of the Fe-S 
cluster assembly. There are isc and suf pathways together in E. coli (Figure 3.1). Isc 
pathway is the housekeeping pathway for Fe-S cluster assembly while Suf pathway 
produces Fe-S clusters under oxidative stress and iron starvation. The Suf pathway is 
encoded by the suf operon composed by sufABCDSE (Figure 3.2). SufS is homologous to 
IscS as cysteine desulfurase to extract sulfur from L-cysteine, which forms a persulfide on 
its active site (Cys364-S-SH). Then the sulfur is transferred to the active site of SufE 
(Cys51-S-SH), which transfers this sulfur atom to the scaffold protein SufBC2D as a sulfur 
shuttle. In the Suf pathway, SufBC2D acts as the scaffold protein where the nascent Fe-S 
cluster is formed with Fe donation. SufA is homologous to IscA, which is a shuttle of the 
Fe-S cluster from the scaffold protein to the target apo protein6,10. The basal activity of 
SufS is low that the activity of IscS is up to 20-fold higher than SufS. SufE can enhance 
the activity of SufS to a level comparable to IscS11. SufBC2D can further increase the 
activity of SufS-SufE complex12. Under stress conditions, both IscS and IscS-IscU 
complex are much more sensitive to H2O2 exposure than SufS-SufE complex that still 
maintains a high activity as the concentration of H2O2 increases. The active site of SufS is  
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Figure 3.1 Comparison of isc and suf pathway and the function of each component. 
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Figure 3.2. Current model of Suf pathway. 
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more resistant to oxidation modification in the presence of SufE. The interaction of SufS 
and SufE is essential to activate SufS and provide protection against oxidative stress11. 
However, the interface of this interaction is still unknown. This research on the interface 
of the interaction between SufS and SufE has a potential to develop an inhibitor to disrupt 
the binding of SufE in order to decrease the activity of SufS, which has biomedical 
relevance. The suf pathway is conserved in various bacteria like Mycobacterium 
tuberculosis, Shigella and even our model system, E. coli. They are important infectious 
pathogens. It has been shown that the suf pathway is essential for bacterial survival under 
iron deprivation conditions, which is a common setting bacteria confront in the human 
body. Because of lack of direct homologs of Suf proteins in humans, disruption of the Suf 
pathway with novel antibiotics should have minimal side effects13.  
            CsdA and CsdE are homologous to SufS and SufE individually. Both CsdA and 
SufS belong to the group II cysteine desulfurase with ~ 43% sequence identity (Figure 3.3). 
CsdE and SufE have ~ 35% sequence identity (Figure 3.4). The sequence similarity  
suggests that CsdA/CsdE and SufS/SufE are closely relative. The crystal structure of the 
complex of CsdA-CsdE has been resolved. The helix16, helix18 β sheets and the active 
site loop of CsdA are the main parts of the interaction with CsdE (helix-II, active site loop, 
helix-III and a part of helix-VI) (Figure 3.5). This interaction causes a significant 
conformational change of the active site loop of CsdE from being buried in the hydrophobic 
pocket to shift towards CsdA by moving ~ 11 angstroms upon binding of CsdA. The 
residues in the interface of CsdA-CsdE interaction are highly conservative in SufS and 
SufE, which suggests the SufS-SufE interface may resemble that of CsdA-CsdE14. Amide 
hydrogen/deuterium exchange mass spectrometry (HDX-MS) is used to characterize the  
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Figure 3.3. Alignment of CsdE and SufE. The secondary structure of CsdE was shown 
using the CsdE pdb file 5EEP.   
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Figure 3.4. Alignment of CsdA and SufS. The secondary structure of CsdA was shown 
using the CsdA pdb file 5FT4. 
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Figure 3.5. Interface of the interaction between CsdA and CsdE14.  CsdA is green. CsdE 
is yellow. 
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SufS and SufE interaction. The result shows residue 38 – 56 and/or 66 – 83 of SufE, 225 – 
236 and 356 – 366 of SufS, have altered deuterium uptake, which means conformational 
change after the interaction15. Residue 38 – 56 and 66 – 83 of SufE are corresponding to 
the interface region of CsdE. Reside 356 – 366 of SufS is the active site loop that 
corresponds one part of the interface regions of CsdA. Residue 225 – 236 locates in the 
deep cavity of the active site which is impossible to participate in the interaction but related 
in the activation mechanism of SufS. Based on the CsdA-CsdE co-structure, 343 – 354 
(helix16) and 393 – 406 (helix18) of SufS are also possible to form hydrogen bonds and 
van der Waals with SufE but they do not show a significant change in the HDX-MS data 
of SufS-SufE interaction15. This finding led us to investigate the possible interface in the 
reaction of SufS and SufE. 
            Here we show the activity of SufS Y345A/D346A cannot be enhanced by SufE. 
And there is no interaction between SufS Y345A/D346A. Our results thus show that 
Tyr345 and Asp346 of SufS play an important role in the interface of the interaction of 
SufS and SufE. The binding of SufE to SufS is essential to its enhancement to the activity 
of SufS, which may be relative to the sulfur transfer from SufS to SufE. According to the 
current data, we propose a simulation of the interface of the interaction of SufS and SufE 
to further clarify this interaction. 
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MATERIALS AND METHODS 
           Plasmid and Site-mutagenesis  
            For mutagenesis of sufS, pET21a_sufS was used as the template plasmid. The SufS 
Y345A/D346A double mutation was introduced by site-directed mutagenesis using the 
QuikChange Kit (Stratagene) with primers 5’-AACACCACGCCGCTGCTGTTGGCAG-
3’ and its complementary primer 5’-CTGCCAACAGCAGCGGCGTGGTGTT-3’ on 
pET21a_sufS. For the SufS S262A/E263A double mutation, the primer was 5’-
CAGCCTGGCTGCAGGCACTA-3’ and its complementary primer was 5’-
TAGTGCCTGCAGCCAGGCTGA-3’ on pET21a_sufS. The mutations were confirmed 
by DNA sequencing and alignment. 
 
            Protein expression and purification 
            E. coli SufS and SufE were independently expressed and purified as described 
previously. E. coli BL21(DE3) containing pET-21a_SufS Y345A/D346A or pET-21a_SufS 
S262A/E263A was grown in LB with 100 μg/ml ampicillin at 37 ˚C for overnight, diluted 
100 fold into LB, incubated with shaking to reach an OD600 of 0.4 – 0.6 before induced by 
500 µM IPTG at 18 ˚C for overnight. Cells were harvested and lysed in 25mM Tris-HCl, 
pH 8.0, 5mM DTT, and 1 mM PMSF via sonication. After centrifugation at 14000 rpm for 
30min, the lysate was loaded on the columns. The SufS mutants were purified through Q-
sepharose, phenyl and Superdex 200 chromatography resins in sequence. The Q-sepharose 
column used a linear gradient from 25 mM Tris-HCl, pH 8.0, 10 mM βME to 25 mM Tris-
HCl, pH 8.0, 1 M NaCl, 10 mM βME. The phenyl column utilized a linear gradient from 
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25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1M ammonium sulfate, 10 mM βME to 25 mM 
Tris-HCl, pH 8.0, 10 mM βME. The Superdex column run with 25 mM Tris-HCl, pH 8.0, 
150mM NaCl, 10 mM βME. Purified proteins were concentrated, frozen as drops in liquid 
nitrogen, and stored at – 80 ˚C until further use. 
 
            Ultraviolet-visible Spectroscopic Analysis 
            Ultraviolet-visible (UV-vis) spectra were measured by a BECKMAN COULTER 
DU 800 spectrophotometer. SufS Y345A/D346A and WT SufS were prepared at the 
concentration of 20 µM in 25 mM Tris-HCl, 150 mM NaCl, pH 8.0 buffer. 180 – 500 nm 
spectra were collected with a cuvette of 1 cm path length.  
 
            PLP quantification 
            The PLP cofactor is essential for the activity of SufS. PLP quantification can 
measure the percentage of PLP in SufS, which indicates the structural integrity of this 
enzyme.  The protein was diluted into 1-2 mg/ml of 800 uL sample in 10 mM Tris-HCl, 
pH 8.0 buffer. 200 uL 5M NaOH was added and incubated at 75 ˚C for 10 min. Then 85 
μL 12 M HCl was added. The sample was centrifuged at the highest rpm for 2 min. The 
UV-visible absorption was read at 390 nm. A PLP quantification standard line (Figure 3.6) 
was used to calculate the concentration of PLP in the sample. 
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Figure 3.6. PLP quantification standard line and its linear fitting.  The fitting line is y = 
0.0211x + 0.0026.   
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            Analytical gel filtration analysis             
            Analytical Superdex 200 gel filtration column (GE Healthcare) was used for the 
analytical gel filtration analysis to compare the molecular weight (MW) of WT SufS and 
SufS Y345A/D346A. The sample volume is 25 uL and the amount of protein is 1 mg. The 
flow rate is 0.5 mL/min and the elution buffer is 10 mM Tris-HCl, 150 mM NaCl, pH 8.0. 
The standard line was used to calculate the MW of the protein. 
 
            Circular Dichroism Spectroscopic Analysis 
            Circular dichroism (CD) spectra were measured by a JASCO J815 
spectropolarimeter (JASCO, Essex, UK) at 20 ˚ C. SufS Y345A/D346A and WT SufS were 
prepared at the concentration of 20 µM in 25 mM boric acid, pH 8.0 buffer. Far-ultraviolet 
(180 - 300 nm) spectra were collected with a cuvette of 1 cm path length. 
 
            Isothermal Titration Calorimetry 
            Isothermal titration calorimetry (ITC) measurements were performed on a VP-ITC 
calorimeter (MicroCal) at 20 ˚C. In the SufS/SufS Y345A/D346A and SufE ITC 
experiment, 1.44 ml 50 µM SufS or SufS Y345A/D346A present in the cell was titrated 
with 45 x 6uL injections of 1.1 mM SufE (10-fold molar excess over SufS/SufS 
Y345A/D346A). The duration of each injection was 7.2 s (1.2 s/μL), with an interval of 
200 s between injections. Each experiment was corrected by the endothermic heat of 
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injection resulting from the titration of SufE into the buffer without protein. SufS/SufS 
Y345A/D346A ITC data wre analyzed in MicroCal Origin.   
 
            Cysteine Desulfurase Activity Assay 
            Cysteine desulfurase activity was measured through the formation of methylene 
blue with NNDP and FeCl3 using the protocol below. Reactions were conduct aerobically 
in 25mM Tris-HCl, pH 7.4, 150 mM NaCl at room temperature. 0.5 µM proteins were 
incubated in the buffer for 5 min before the addition of 2 mM L-cysteine and 2 mM DTT. 
The reaction volume was 800 uL. Reactions proceeded for 10 min and were quenched by 
100 uL 20mM NNDP in 7.2 M HCl and 100 uL 30 mM FeCl3 in 1.2 M HCl. The mixture 
was incubated in the dark for 30 min to produce methylene blue. Precipitated protein was 
removed by 1 min centrifugation at 13000 rpm and the methylene blue was measured at 
670 nm. A Na2S standard line was made for calibration of the content of sulfur product 
from this reaction. 
 
            Protein-protein Interface Simulation through Protein Docking 
            To get an insight into the interaction interface of SufS and SufE, docking of SufS 
and SufE was performed with the GRAMMX server 
(http://vakser.bioinformatics.ku.edu/resources/gramm/grammx/), which applies extensive 
refinement, smoothed potentials, and knowledge-based scoring with fast Fourier transform 
global search methodology to predict the structure of a protein complex. 
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RESULTS 
            Structural integrity of SufS Y345A/D346A 
            The crystal structure of SufS shows that the PLP-binding site and active site 
residues are located in a narrow cavity within the SufS homodimer16. Around the cavity 
opening of SufS, there are several polar residues, like Tyr345/Asp346 (Fig. 3.7). Polar 
residues of amino acids may play a role in the interaction of proteins17. To check if 
Tyr345/Asp346 play a role in the binding of SufS and SufE, the Tyr345Ala and Asp346Ala 
double mutation of SufS was constructed through codon substitutions (SufS 
Y345A/D346A). Mutation may cause influence to the original structure, even breakdown 
of the tertiary and quarternary structures of a protein. To check its structural integrity, we 
checked the PLP occupancy of SufS Y345A/D346A through a PLP quantification assay 
and it turns out to be above 90%. The pure SufS Y345A/D346A also was analyzed by the 
analytical Superdex-200 gel filtration (Figure 3.8). The results show that the mutant SufS 
almost overlays WT SufS and the molecular weight of the mutant SufS is smaller than WT 
SufS, which is consistent with the calculation based on the protein sequence. We applied 
UV-vis spectrum analysis. SufS is a PLP-dependent enzyme with a UV-visible absorption 
at 420 nm which represents the internal aldimine. Internal aldimine is the Shiff base that 
PLP cofactor binds covalently with a SufS Lys residue. Any shift of this absorption peak 
means there is a significant change of the SufS structure, which may lead to loss of activity.  
The UV-vis spectrum of SufS Y345A/D346A shows that the mutant still has the PLP-
characteristic absorption peak around 420 nm. It indicates that this mutation does not 
disturb the PLP cofactor of SufS (Figure 3.9). 
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Fig. 3.7. Crystal structure of the polar residues around the cavity opening of the active 
site of SufS. 
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Figure 3.8. Analytical gel filtration analysis of WT SufS and SufS Y345A/D346A. Ve is 
elution volume. Kav is an elution volume parameter.  
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Figure 3.9. Overlay of the UV-visible spectra of WT SufS and SufS Y345A/D346A.  
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            Circular dichroism (CD) is the difference in absorption between the left and right 
hand circularly polarized light in chiral molecules. The CD spectroscopy in the far UV 
region (180 nm – 250 nm) is used to probe the secondary structures of proteins18. To check 
if the double mutations change the secondary structure of SufS, we applied CD 
spectroscopy analysis to SufS Y345A/D346A. The result of CD shows that the spectra of 
WT SufS and SufS Y345A/D346A match each other well, which indicates that the double 
mutations do not disturb the secondary structure of SufS (Fig. 3.10). 
 
            Activity of SufS Y345A/D346A in the L-cysteine desulfurase reaction 
            To test the activity of SufS Y345A/D346A in the L-cysteine desulfurase reaction, 
we utilized the cysteine desulfurase assay to check the activity of SufS Y345A/D346A in 
the absence or presence of SufE. Cysteine desulfurases, like SufS, can mobilize the sulfur 
from L-cysteine to form alanine and a persulfide sulfur. The activity of the cysteine 
desulfurase can be determined by quantifying the amount of persulfide (S-SH) species on 
SufS after reduction to sulfide (SH) using DTT, TCEP, or excess L-cysteine. We first 
checked the activity of the SufS Y345A/D346A in function of various concentration of L-
cysteine without the enhancement of SufE (Figure 3.11). The result suggests that the 
mutant SufS has a similar basal activity as WT SufS without the enhancement of SufE. 
Then we checked the enhancement of SufE to the activity of the mutant SufS (Figure 3.12). 
The result shows that as the concentration of SufE increases, the activity of WT SufS 
increases significantly while SufS Y345A/D346A does not respond to the presence of 
SufE. Thus SufE does not enhance the activity of SufS Y345A/D346A. 
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Fig. 3.10. Overlay of the CD spectra of WT SufS and SufS Y345A/D346A. 
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Figure 3.11. The comparison of activities of WT SufS and SufS Y345A/D346A in function 
of the concentration of L-cysteine in the absence of SufE. (A) Activity of WT SufS. (B) 
Activity of SufS Y345A/D346A. 
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Figure 3.12. Comparison of activities of 0.5 µM WT SufS and 0.5uM SufS Y345A/D346A 
in the presence of various concentration of SufE. 
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            Affinity of SufE to SufS Y345A/D346A 
            Isothermal titration calorimetry (ITC) directly measures the heat generated or 
absorbed when molecules interact and provides thermodynamic parameters like enthalpy, 
entropy, and kinetics of interactions like Km, Kcat, and the heat rate in solution, which can 
indicate the interactions of molecules19. For the interaction, ITC can provide the number 
of binding site (n) and the dissociation constant (Kd). There is direct evidence from ITC 
that SufS binds to SufE15. To check the affinity between SufE and SufS Y345A/D346A, 
we used SufE to titrate SufS Y345A/D346A in ITC. The ITC result shows there is no 
obvious endothermic process during the whole titration and the data cannot fit any model, 
which indicates that no detectable interaction is observed (Figure 3.13). This result shows 
that the mutation of SufS Y345A/D346 inhibits the interaction with SufE so SufE cannot 
enhance the activity of the cysteine sulfurase, but we still cannot exclude the possibility 
that the mutation also disrupts the structure of SufS. 
 
            Activity of SufS S262A/E263A in L-cysteine desulfrase reaction 
            Like Tyr345/Asp346, Ser262/Glu263 are also located at the opening of the cavity 
containing the active site of SufS (Figure 3.14). The Location of Ser262 and Glu263 on 
polar “knob” present on the active site “lid” around the opening of the cavity containing 
the active site of SufS. The HDX-MS data shows that a slow H/D exchange was observed 
in the region of residue 262-274 of SufS (Figure 3.15). Ser262/Glu263 are polar residues 
which may form hydrogen bonds with SufE and contribute to the interaction between SufS 
and SufE. We mutated both Ser262 and Glu263 to Ala (SufS S262A/E263A) and checked 
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Figure 3.13. Analysis of the binding of SufS Y345A/D346A and WT SufE by isothermal 
titration calorimetry. The integrated heats of the binding plotted against the molar ratio of 
SufE added to the mutant SufS showed random dots, which indicates there is no interaction 
between the two proteins above. 
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Figure 3.14. Location of Ser262/Glu263 on the surface of SufS. The cyan part is the “lid” 
around the opening of the active site of SufS. 
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Figure 3.15. Crystal structure of the surface of SufS. The pink region (Residue 262-274) 
shows a slower H/D change. 
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its influence on SufS activity. The result shows that SufE can still enhance the activity of 
SufS S262A/E263A (Figure 3.16). Compared with the data of SufS Y345A/D346A, 
Ser262 and GLu263 may not participate in the interaction of SufS and SufE. 
 
            Structural modeling of the SufS-SufE interaction 
            Since the crystallography structure of a SufS-SufE complex is not solved yet, we 
used the crystal structure of SufS (PDB accession NO. 1C0N) and SufE (PDB accession 
NO. 1MZG) of E. coli to predict the interaction between SufS and SufE by protein-protein 
docking with the GRAMM-X docking server. 30 possible solutions for the SufS-SufE 
interaction were generated, one of which was selected based on the similarity as the 
interaction of CsdA-CsdE14, the HDX-MS data of the apo SufS and the apo SufE15 and the 
predicted proximity of the cysteine residues at the active sites of SufS and SufE (Figure 
3.17). SufS and SufE are homodimers. In the interaction model, only one monomer of SufS 
interacts with one monomer of SufE. The other monomers of the homodimers have no 
interaction. The loop containing the active site Cys51 of SufE is flipped towards the active 
site Cys364 of SufS to reduce the distance between the sulfur atoms of the two cysteines, 
which is a better orientation for the transpersulfide reaction. The β helix containing Tyr345 
and Asp346 of SufS is proximal to the helixes of SufE and hydrogen bonds are formed, 
which are essential for the interaction between SufS and SufE.   
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Figure 3.16. Comparison of activities of 0.5 µM WT SufS and 0.5uM SufS S262A/E263A 
in the presence of various concentration of SufE. 
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Figure 3.17. Binding interface simulation of the interaction of SufS and SufE through 
protein-protein docking.  SufS is green. SufE is yellow. The orange part is the interface of 
the interaction.  
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DISCUSSION 
            Recent advances have made protein-protein interactions (PPIs) new targets for 
inhibitor design. Protein crystallography and mutational analysis have revealed that not all 
the residues at the interaction interface are critical but some “hot spot” residues provide 
most of the binding energy through hydrogen bonds and Van der Waals’ forces20. Small 
molecules that bind to the hot spots can disrupt the PPI and inhibit the function of the 
protein-protein complex21. The research on the interaction of SufS and SufE has a potential 
to develop a type of PPI which can solve the problem of the specificity of the traditional 
SufS inhibitor. In this study, we proposed the hypothesis that the polar residues around the 
opening of the active site of SufS may participate in the interaction of SufS and SufE. To 
prove it, we applied site-directed mutagenesis and characterize the possible binding sites 
by CD, ITC, cysteine desulfurase assay and computational protein docking. The results 
show that the mutation of SufS Y345A/D346A keeps its structural integrity of the protein 
but it loses its affinity to SufE and it cannot be enhanced by SufE. The structural modeling 
of the SufS-SufE interaction by protein docking shows that the polar residues Tyr345 and 
Asp346 are located at a β helix beside the active site of SufE which is proximal to a helix 
of SufE and hydrogen bonds are formed. These findings are consistent with our hypothesis. 
            In our former research of the interaction between SufS and SufE, the ITC of apo 
SufS and apo SufE shows that there is a biphasic behavior in the binding process. At lower 
SufE concentration, it is an exothermic phase. At higher SufE concentration, it is an 
endothermic phase. The binding of SufE to SufS is best fit by a sequential two-site binding 
model with a higher affinity site and a lower affinity site15. It indicates that: first, SufE 
binds to SufS; second, each monomer of the homodimer of SufS has different affinity to 
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SufE. One SufE binding to one monomer of SufS can change the binding of the other 
monomer of SufS with another SufE. In the current study, we make the mutation of SufS 
Y345A/D346A. The ITC of apo SufE and apo SufS Y345A/D346A shows that there is no 
obvious binding between SufE and this mutant. It indicates that the double mutant breaks 
the interaction between SufS and SufE. We further checked the activity of SufS 
Y345A/D346A. The result shows that SufE cannot enhance the activity of the mutant SufS. 
The reason may be due to the loss of the interaction between them. So it is safe to say 
Tyr345 and Asp346 are important in the interaction of SufS and SufE. They are the “hot 
spot” residues that provide binding energy most likely from hydrogen bond in the SufS-
SufE interaction and are candidates for the design of PPIs for SufS.  
            The crystal structure of CsdA-CsdE shows that the binding interface in CsdA 
includes helix16, helix18 and the active site loop14. CsdA and CsdE are homologous to 
SufS and SufE. Both CsdA and SufS are group II cysteine desulfurases. So the binding 
behaviors of CsdA has special meaning in the research of the binding of SufS and SufE. 
Based on the CsdA-CsdE crystal structure, the binding interface of SufS is supposed to be 
the residues of 343-354 (helix16), 355-378 (active site Cys364 loop), 393-406 (helix18). 
However, our former research on the SufS-SufE interaction through HDX-MS shows 
residue 356-366 of SufS are involved in the binding process15. The first explanation to this 
difference is that the SufS and SufE interaction may not be completely analogous to that 
of CsdA and CsdE. The second explanation may be that the binding of residue 343-354 
and 393-406 may be not as significant as the residue 356-366. Our current study shows that 
Tyr345 and Asp346 in the residue 343-354 are essential for the interaction of SufS and 
SufE. It indicates that besides the residue 356-366, at least residue 343-354 also participate 
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in the binding. From our structural modeling of the SufS and SufE interaction, the loop 
containing the active site Cys364 of SufS is very close to the active site loop of SufE, which 
may provide larger binding energy compared with the rest binding interface. So our current 
research supports the second explanation of this difference. 
             In summary, we applied site-directed mutations and ITC to investigate the 
interaction of SufS and SufE. The UV-vis and CD show that the mutation still has the 
integral structure. The ITC shows that the mutation SufS Y345A/D346A loses its affinity 
with SufE. The cysteine desulfurase assay shows that SufE cannot enhance the activity of 
this mutant any more. Finally, we generated a structural binding model of SufS and SufE 
with computational protein docking. All the results above indicate that Tyr345 and Asp346 
are essential in the binding of SufS and SufE. The interruption of the two residues above 
can make SufS-SufE complex lose its activity. Our further work will be required to further 
clarify this interaction and to screen or design the protein-protein inhibitor based on the 
interaction interface of SufS and SufE. 
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CHAPTER 4 
EFFECTS OF PLP-BASED INHIBITORS CYCLOSERINE AGAINST 
SUFS AND SUFE AND THEIR MECHANISMS 
 
ABSTRACT 
            Suf pathway is necessary for Fe-S cluster biogenesis under oxidative stress and 
iron-limiting conditions. It is a good target for novel antibiotic design. SufS is the cysteine 
desulfurase in Suf pathway to extract sulfur from L-cysteine. It needs the enhancement of 
its accessory protein, SufE. The PLP cofactor of SufS is essential to catalyze the β-
elimination reaction of L-cysteine to extract the sulfur. Cycloserine has two enantiomers, 
D-cycloserine (DCS) and L-cysloserine (LCS), which are irreversible inhibitors of PLP 
dependent enzymes by forming a stable adduct with the PLP cofactors. To investigate if 
DCS/LCS can inhibit the activity of SufS, we checked the activity of SufS in the presence 
of either DCS or LCS. The results show that there is a dose-dependent inhibition of SufS 
activity by DCS. The 50% inhibitory concentration (IC50) was calculated to be 1.98 mM. 
A dose-dependent inhibition of SufS by LCS was also observed and the IC50 is 306.1 µM 
Compared with DCS, LCS shows much better inhibitory effects. The small-molecular 
docking shows that the nitrogen of DCS to start the nucleophilic attack towards the Schiff 
base of the PLP and Lys226 is far away from its target, which is not a proper orientation 
for the transimination reaction. The docking of LCS shows that the nitrogen of LCS for the 
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nucleophilic attack is close to the Schiff base of Lys226 and PLP, which is a proper 
orientation for the following transimination reaction. The UV-visible spectra of SufS and 
DCS shows the degradation of internal aldimine and a new intermediate at 380 nm is 
formed. The spectrum of LCS shows the 380 nm peak is reduced but a 320 nm peak keeps 
growing, which indicates the intermediate at 320 nm is a stable adduct and it is hard to get 
rescued by excessive L-cysteine. A reaction mechanism is proposed to depict the reaction 
between SufS and DCS/LCS. 
 
INTRODUCTION 
            Iron is essential for most organisms in which it performs a wide variety of vital 
cellular functions. Many of these functions depend on iron-sulfur (Fe-S) clusters. Fe-S 
clusters are key metal cofactors in electron transfer, catalysis, sensing of reactive oxygen, 
and genetic regulation1. The biosynthesis of Fe-S clusters is undertaken by a series of 
proteins working cooperatively. In Escherichia coli (E. coli), the Suf pathway is necessary 
for Fe-S cluster biogenesis under oxidative stress and iron-limiting conditions2. The Suf 
pathway is a good target for novel antibiotic design because: First, the Suf pathway is 
conserved in important pathogens like Mycobacterium tuberculosis and Shigella as well as 
in our model system, E. coli3. Second, the Suf pathway is essential under oxidative stress 
and iron limiting conditions which confront bacterial pathogens in the human body4,5. 
Third, humans lack direct homologues of most of the Suf proteins, so disruption of the Suf 
pathway should have minimal side effects6. SufS is the cysteine desulfurase in Suf pathway 
that extracts sulfur from the L-cysteine for sulfur donation to nascent Fe-S cluster 
formation. It has an important cofactor, pyridoxal-5’-phosphate (PLP), located in the active 
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site of SufS that plays a key role in the desulfurase reaction7. SufE is another protein from 
the same suf operon as SufS8. SufE interacts with SufS and this interaction enhances the 
activity of SufS by accelerating the sulfur release from SufS. SufS itself has low activity. 
SufE also protects the SufS active site from oxidative stress5.  
            The cysteine desulfurase like SufS utilizes the PLP cofactor at the active site to 
catalyze the β-elimination reaction of L-cysteine to extract the sulfide from this amino 
acid9. The crystal structure of SufS from E. coli clearly shows that this cofactor covalently 
attached to the side-chain of a conserved Lys226 via a Schiff’s bass (Figure 4.1). This is 
also known as an internal aldimine and is located at the cavity of the active site10. 
Transaldimination occurs when the L-cysteine substrate binds at the active site to form an 
external aldimine11. The crystal structure of external aldimine is not resolved due to the 
fast turnover. However, the structure of L-propargylglycine bound to PLP is resolved, 
which proves the presence of the transaldimination reaction12 (Figure 4.2). The proposed 
steps subsequent to the formation of the external aldimine are (Figure 4.3): deprotonation 
at the α carbon of the external aldimine to form a quinonoid intermediate; the quinonoid is 
not stable and generates external ketimine; the active site Cys364 starts a nucleophilic 
attack to get the sulfide from external ketimine and the PLP is regenerated to release the 
Ala after a series of reactions9. PLP that plays an essential role in the desulfurase reaction 
is a good target for specific inhibitors. 
            Cycloserine has two enantiomers, D-cycloserine (DCS) and L-cysloserine (LCS) 
(Figure 4.4). Both of them can be used as cyclic analogues of cysteine, serine, and/or 
alanine. They have been shown to be irreversible inhibitors of many PLP-dependent 
enzymes like transaminases13, racemases14 and decarboxylases15. DCS also shows an  
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Figure 4.1 Crystal structure of internal aldimine in the active site of SufS. 
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Figure 4.2. Crystal structure of L-propargylglycine bound to PLP in SufS. 
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Figure 4.3 Proposed mechanism of the reaction between SufS and L-cysteine.  
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Figure 4.4. Chemical structures of DCS, LCS, and L-cysteine. 
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inhibitive effect on the desulfurase reaction of pSufS, which is the cysteine desulfurase in 
Plasmodium falciparum16. DCS is a natural product from Streptomyces strains and acts as 
a broad spectrum antibiotic, whereas LCS is synthesized chemically17. DCS has severe side 
effects so it is most commonly used as a second-line antibiotic in the combination therapy 
to treat tuberculosis18. Its main antibacterial target is the PLP-dependent alanine racemase 
which is an essential enzyme generating D-alanine for the formation of the D-alanyl-D-
alanine dipeptide incorporated into the bacterial peptidoglycan layer19. DCS is also a potent 
agonist of N-methyl-D-aspartic acid (NMDA) receptor involved in human 
neurotransmission20. LCS commonly regulates the lipid metabolism but its mechanism of 
inhibition is still unknown. Unlike many irreversible inhibitors that inactivate their protein 
targets by covalent modification, cycloserine forms a stable adduct with the PLP cofactors 
to inhibit16.  
            SufS is a PLP-dependent enzyme and PLP is essential for the desulfurase reaction. 
Cycloserine is a good candidate as a specific inhibitor to decrease the activity of SufS. In 
this study, we used a combination of enzyme kinetics, computational protein docking, and 
UV-vis spectroscopy to elucidate the mechanism of SufS inactivation by both enantiomers 
of cycloserine. We highlight differences in the inhibition from DCS and LCS and provide 
further insight in the PLP-dependent reaction.       
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MATERIALS AND METHODS 
            Strains and Plasmids 
            SufS and SufE were expressed in BL21(DE3). The construction of the vectors, 
pET21a_sufS and pET21a_sufE, were described before5. Cells that overexpress SufS and 
SufE were grown in Lennox Broth (LB). 100 mg/L ampicillin was used. All chemicals 
were obtained from Sigma unless otherwise indicated. 
 
            Protein Expression and Purification 
            E. coli BL21(DE3) containing pET21a_sufS and pET21a_sufE vectors was grown 
in LB at 37 ˚C until it reached an OD600 of 0.4 - 0.6. The overexpression was induced by 
addition of 500 µM IPTG. The condition for the induction of SufS is 18 ˚C overnight. The 
SufE induction condition is 37 ˚C for 3 hours. Cells were harvested and lysed in 25mM 
Tris-HCl, pH 8.0, 5mM DTT, and 1 mM PMSF via sonication. After centrifugation at 
14000 rpm for 30min, the lysate was loaded on the columns. SufS was purified through Q-
sepharose, phenyl and Superdex 200 chromatography resins in sequence. SufE was purified 
through Q-sepharose and Superdex 200 chromatography resins in sequence. The Q-
sepharose column used a linear gradient from 25 mM Tris-HCl, pH 8.0, 10 mM βME to 25 
mM Tris-HCl, pH 8.0, 1 M NaCl, 10 mM βME. The phenyl column utilized a linear 
gradient from 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1M ammonium sulfate, 10 mM 
βME to 25 mM Tris-HCl, pH 8.0, 10 mM βME. The Superdex column run with 25 mM 
Tris-HCl, pH 8.0, 150mM NaCl, 10 mM βME. Purified proteins were concentrated, frozen 
as drops in liquid nitrogen, and stored at – 80 degrees until further use. 
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            Rates of SufS-SufE inactivation by cycloserine using cysteine desulfurase assay 
            The activity of SufS and SufE was measured using the methylene blue assay as 
previously described5. Reactions were conduct aerobically in 25mM Tris-HCl, pH 7.4, 150 
mM NaCl at room temperature. 0.5 µM SufS and 2 µM SufE proteins were incubated with 
DCS (0 µM, 10 µM, 50 µM, 100 µM, 500 µM, 1000 µM, 2000 µM, 5000uM) or LCS (0 
µM, 10 µM, 50 µM, 100 µM, 500 µM, 1000 µM, 2000 µM, 5000uM) in the buffer for 5 
min before the addition of 2mM L-cysteine and 2mM DTT. The reaction volume was 800 
uL. Reactions proceeded for 10 min and were quenched by 100 uL 20mM NNDP in 7.2 M 
HCl and 100 uL 30 mM FeCl3 in 1.2 M HCl. The mixture was incubated in the dark for 30 
min to produce methylene blue. Precipitated protein was removed by 1 min centrifugation 
at 13000 rpm and the methylene blue was measured at 670 nm. A Na2S standard line was 
made for calibration of the content of sulfur product from this reaction. 
 
            Docking study of cycloserine into SufS 
            Flexible-ligand docking studies were done by AutoDock 4.2 program. All the pre-
processing steps for the ligand DCS/LCS and the receptor SufS crystallographic files were 
performed within the AutoDock Tools 1.5.4 program (ADT). All hydrogens were added to 
the receptor PDB file by the ADT program. For docked ligands, non-polar hydrogens were 
added; Gasteiger charges assigned and torsions degrees of freedom were also allocated by 
ADT program. A grid of 60 x 60 x 60 points in x, y, and z direction was built centered at 
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the center of the active site of SufS. Cluster analysis was performed on the docking results 
using an RMS tolerance of 2 angstroms.  
 
            UV-visible secptroscopy of SufS-SufE inhibition by cycloserine 
            Ultraviolet-visible (UV-vis) spectra were measured by a BECKMAN COULTER 
DU 800 spectrophotometer. 25 µM SufS, 100 µM SufE and 5mM DCS or LCS were 
prepared at the concentration of 20 µM in 25 mM Tris-HCl, 150 mM NaCl, pH 8.0 buffer. 
180 – 500 nm spectra were collected with a cuvette of 1 cm path length at time intervals 
from 0 min to 2 hours.   
RESULTS 
            Inhibitory effects of DCS and LCS on the activity of SufS in the presence of SufE 
            The native activity of SufS alone is very low compared with its homologue IscS. 
The SufS and SufE complex reaches a comparable level of activity with IscS5. So we used 
SufS and SufE with a 1:4 ratio in the cysteine desulfurase assay to check its activity. The 
active site of SufS includes the PLP cofactor bound to the conserved Lys226. Inhibitors of 
PLP-dependent enzymes that bind with this cofactor have been used as irreversible 
inhibitors for the activity of the enzyme. DCS reacts with the PLP fold type 1 enzymes like 
aspartate aminotransferase family to inhibit their activities18,20,21. Since cysteine 
desulfurase like SufS also belongs to the PLP fold type 1 enzymes22, DCS may act as an 
inhibitor to SufS. The effect of DCS on the desulfurase activity of SufS was investigated. 
DCS was incubated with SufS and SufE. There was a dose-dependent inhibition of SufS 
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activity by DCS (Figure 4.5). The 50% inhibitory concentration (IC50) was calculated to be 
1.98 mM. The inhibitory effect of DCS on the desulfurase activity of SufS is poor. To 
further investigate the inhibitory mechanism of cycloserine on SufS, we used LCS that is 
an enantiomer to DCS with a chiral symmetry. A dose-dependent inhibition of SufS by 
LCS was also observed and the IC50 was 306.1 µM (Figure 4.6). Compared with DCS, LCS 
shows much better inhibitory effects.      
 
            Small-molecular docking of cycloserine into SufS 
            Docking is a method to predict the preferred orientation of one molecule to another 
to form a stable complex. It is commonly used in the field of molecular modeling. Small-
molecular docking is used to predict the binding conformation of small molecule ligands 
to the target binding site23. In this study, we docked both DCS and LCS into SufS to 
investigate the difference of their inhibitory effects on SufS. We first docked the substrate 
L-cysteine into the active site of SufS as a control (Figure 4.7). L-cysteine is stabilized by 
His123, Arg359, and Thr278 (from the other monomer) through hydrogen bond. The 
nitrogen of the L-cysteine is at a proper orientation towards the Schiff base between the 
PLP cofactor and the conserved Lys226, which facilitates the reaction of transimination. 
DCS is a cyclic analogue of cysteine. After it is docked into the active site of SufS, it is 
also stabilized by His123, Arg359, and Thr278 (Figure 4.8). However, the nitrogen of DCS 
to start the nucleophilic attack towards the Schiff base of the PLP and Lys226 is far away 
from its target, which is not a proper orientation for the transimination reaction. The 
transimination reaction between DCS and the internal aldimine is hard to happen. It may 
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Fig. 4.5. Activity of 0.5 µM SufS and 2 µM SufE at various concentration of DCS.  
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Figure 4.6. Activity of 0.5 µM SufS and 2 µM SufE at various concentration of LCS. 
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Figure 4.7. Docking model of L-cysteine as a substrate into the active site of SufS.  
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Figure 4.8. Docking model of DCS into the active site of SufS. 
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explain why the inhibitory effect of DCS on SufS is poor. LCS is an enantiomer to DCS 
and is chiral with DCS. The docking of LCS shows that the nitrogen of LCS for the 
nucleophilic attack is close to the Schiff base of Lys226 and PLP, which is a proper 
orientation for the following transimination reaction (Figure 4.9). It may explain why LCS 
shows a better inhibitory effect compared with DCS.  
 
            UV-vis spectroscopy analysis of DCS and LCS binding to SufS 
            The UV-visible spectrum of SufS displays absorbance maxima at 420 nm 
corresponding to the internal aldimine form of the PLP-bound enzyme. When DCS was 
added to SufS at pH 8.0 and 25 ˚C, notable changes in the 420 nm peak occurred (Figure 
4.10), which suggests that DCS interacts with the PLP cofactor. Over a period of 1 hour, 
the internal aldimine peak (420 nm) was reduced to about 10% of its original value with 
simultaneous growth of a new peak at 380 nm. No new peak was observed when the sample 
was incubated for about 2 hours. It suggests that the PLP cofactor bound to the residue 
Lys226 as internal aldimine is replaced by one or more new species.  
            Significant changes in the PLP absorbance spectrum of SufS were also observed 
after the addition of LCS but the changes thereafter were much fast compared with DCS. 
The 420 nm peak went down to about 10% of its original value within 5 min (Figure 4.11), 
which indicates the internal aldimine reacts with LCS to get a new adduct. This 
spectroscopic change correlates with the observation that LCS has a much smaller IC50 
compared with DCS because it is easier to conduct the tranimination reaction with the 
internal aldimine. Meanwhile, two new peaks, 380nm and 320 nm, are formed. Over time  
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Figure 4.9 Docking model of LCS into the active site of SufS. 
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Figure 4.10. UV-visible spectra of addition of 5 mM DCS into 25 µM SufS at various 
time points. 
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Figure 4.11. UV-visible spectra of addition of 5 mM LCS into 25 µM SufS at various 
time points. 
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(2 hours to 12 hours), the 380 nm peak is reduced but the 320 nm peak keeps growing. It 
indicates that the specie of the 380 nm peak may be an intermediate to reach a more stable 
adduct at 320 nm absorbance. The UV-vis spectra of SufS in the presence of DCS and LCS 
are very different to each other. In contrast, the spectra of free PLP in the presence of DCS 
and LCS are identical and display maxima at 360 nm24. Therefore, it is not simply a PLP-
cycloserine aldimine formed in the enzyme. A new specie at 330 nm and a new 
intermediate at 380 nm are formed in the reaction between the cycloserine and the PLP 
cofactor of SufS. 
            L-cysteine can bind to the PLP cofactor to start a transimine reaction, which 
decreases the internal aldimine at 420 nm and increases the external aldimine at 340 nm 
(Figure 4.12).  If the L-cysteine is excessive then the whole reaction is very fast. To test if 
L-cysteine can rescue the inhibition of cycloserine to SufS, we incubated SufS and 
cycloserine for 1 hour before we added L-cysteine. For DCS (Figure 4.13), The absorption 
peak at 380 nm degrades quickly and the absorptions at both 340 nm and 420 nm increased 
as the incubation time extends, which indicates that the intermediate at 380 nm formed by 
SufS and DCS is not stable and SufS can be rescued by L-cysteine. For LCS (Figure 4.14), 
the absorption peak at 380 nm peak decreases slowly and the absorptions at both 340 nm 
and 420 nm increased gradually. A shoulder at 320 nm increased with the 340 nm peak. 
The results indicate that L-cysteine can partially rescue the inhibition from LCS. However, 
even in the presence of L-cysteine, LCS can shift the reaction towards the production of a 
more stable adduct at 320 nm. 
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Figure. 4.12. UV-visible spectra of incubation of 25 µM SufS and 5 mM L-cysteine at 
various time points. 
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Figure 4.13. Change of UV-visible spectra at various time points after adding L-cysteine 
to SufS-DCS complex. We incubated 25 µM SufS and 5 mM DCS for 1 hour before we 
added 5 mM L-cysteine. 
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Figure 4.14. Change of UV-visible spectra at various time points after adding L-cysteine 
to SufS-DCS complex. We incubated 25 µM SufS and 5 mM DCS for 20 min before we 
added 5 mM L-cysteine. 
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DISCUSSION 
            Fe-S clusters are essential for the organism living because they are the key metal 
cofactors in the electron transfer, catalysis, sensing of reactive oxygen, and genetic 
regulation2. Suf pathway is used for the biosynthesis of Fe-S clusters under oxidative stress 
and iron limitation status4. Suf pathway is a good target for novel antibiotic design due to 
its necessity and specificity in bacteria25. SufS and SufE are the beginning of Suf pathway 
to extract sulfur from L-cysteine as a sulfur source for the subsequent Fe-S cluster 
formation. SufS owns a PLP cofactor in its active site which is essential for the cysteine 
desulfurase reaction12. In this study, we applied PLP inhibitor DCS and its enantiomer LCS 
to the desulfurase reaction of SufS to investigate the inhibitory effects and mechanism of 
cycloserine on SufS. The results show that both DCS and LCS inhibit the activity of SufS 
in the presence of SufE and LCS has a better inhibitory effect than DCS. The small-
molecular docking study of DCS and LCS into SufS shows LCS exhibits a better 
orientation towards the Schiff base of the PLP in the rest enzyme, which facilitates the 
transimination reaction. The UV-vis spectroscopic analysis shows that new species at 380 
nm and330 nm are formed after the incubation of DCS/LCS with SufS. The inhibition of 
SufS by DCS and LCS provides evidence for the possibility of inhibitors targeting the PLP 
of this important enzyme of Fe-S cluster biosynthesis. The further research on the 
inhibitory mechanism can be helpful to the design of more potent inhibitors against the 
PLP of this type of enzymes.  
            The kinetics of inactivation of DCS and LCS are quite different. DCS inactivates 
alanine racemase faster than LCS does, which makes it a better antibiotic (seromycine) in 
the therapy of tuberculosis14. In the inhibition of serine palmitoyltransferase, the IC50 of 
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LCS is much lower than that of DCS24. Our study shows that LCS is a better inhibitor than 
DCS in the cysteine desulfurase SufS in E. coli. However, in the inhibitory study of pSufS 
in Plasmodium falciparum, the IC50 of DCS to pSufS is 29 µM16, which is much lower than 
the IC50 of DCS from SufS in E. coli (1.98 mM). The chiral symmetry between DCS and 
LCS may account for the difference of the inactivation kinetics. The orientation of the 
nitrogen of cycloserine towards the Schiff base of PLP in the resting enzyme determines 
its inhibitory potential. After cycloserine binds to the active site of the enzyme, if the 
nitrogen from cycloserine is close enough to the Schiff base of the enzyme PLP for a 
nucleophilic attack, it is a good orientation for inhibition. Otherwise, the inhibitory effect 
is poor. We already used small-molecular docking of DCS/LCS into SufS to prove that 
LCS shows a better orientation towards the Schiff base of the PLP cofactor, which supports 
this explanation.  
            As a commonly used PLP inhibitor, a number of mechanisms of the cysloserine 
inhibition of PLP-dependent enzymes have been proposed26. One of a generally accepted 
mechanism is called “aromatization mechanism”. The incubation of cycloserine and PLP-
dependent enzyme results in a transimination reaction that leads to a cycloserine-PLP 
external aldimine. This external aldimine is not stable. After deprotonation, a stable 3-
hydroxyisoxazole-PMP adduct is formed and the cycloserine ring remains intact and 
covalently linked to the PLP cofactor. This stable adduct contributes to the irreversible 
inhibition of cycloserine to the PLP-dependent enzyme. This mechanism is called 
“aromatization mechanism”. In our UV-vis spectra of SufS and DCS/LCS, the specie at 
380 nm is formed at first. In the case of DCS, the 380 nm peak is formed slowly after the 
internal aldimine (420 nm) is degraded and no further shift is observed. However, in the 
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case of LCS, the 380 nm peak is formed quickly and shift to 320 nm. Based on the UV-vis 
spectroscopic analysis, an inactivation mechanism of DCS/LCS against SufS is proposed 
(Figure 4.15). The specie at 380 nm is cycloserine-PLP external aldimine and the specie at 
320 nm is 3-hydroxyisoxazole-PMP. The shift from 380 nm to 320 nm is caused by 
deprotonation. However, we did not observe the 320 nm peak in the DCS within 2 hours. 
The reason for that may be more time is needed for the formation of the final stable adduct 
because DCS is not in a good orientation for the transimination reaction. Further mass spec 
and crystallography are needed to identify the species at 380 nm and 330 nm in order to 
test this proposed mechanism.  
            The ultimate goal of the research on the inhibitor against SufS is to develop the 
design of a new class of antibiotics. The weakness of cycloserine as an inhibitor to the 
enzyme is its poor specificity. There are a variety of PLP inhibitors based on various 
mechanisms, some of which are very effective. However, the major challenge for PLP 
inhibitors is the specificity when they are used in vivo. Because PLP based enzymes are 
very common in the human body and are principally involved in cellular metabolism, the 
PLP inhibitor may disrupt the normal human cellular function while inhibiting the activity 
of SufS. To solve the problem of specificity of the traditional PLP based inhibitors, protein-
protein interactions (PPI) are new targets for inhibitor design27. This strategy has been used 
successfully to discover small molecular inhibitors of protein complexes such as Il-2/IL-2 
receptor28, LFA1/ICAM29, and P53/MDM230. Our future direction is: first, we will observe 
the growth of E. coli in the presence of DCS/LCS to investigate their inhibitory effect in 
vivo; second, we will investigate the PPI inhibitors that can inhibit SufS specifically.        
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Figure 4.15. Proposed mechanism of inhibition of DCS/LCS against SufS.  
  
 134 
            The inhibition study reports for the first time that cysloserine DCS/LCS can inhibit 
the activity of SufS in the presence of SufE. Small-molecular docking study and UV-vis 
spectroscopic analysis are used to investigate the difference of the inhibitory effects from 
DCS and LCS. A possible inactivation mechanism is proposed. However, further work will 
be required to identify the species at 380 nm and 330 nm in order to confirm this 
mechanism. 
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APPENDIX A – SUPPLEMENTAL EXPERIMENTS AND RESULTS 
 
            Oxidative resistance of SufE_D74R in vivo 
            The interaction of SufS and SufE causes conformational change of the loop 
containing the active site Cys51 in SufE. It has been proved by our former HDX/MS 
experiment. According to the crystal structure of CsdA-CsdE complex that is homologue 
to SufS-SufE, this active site Cys loop may extend from its hydrophobic pocket to the 
active site loop of SufS. Asp74 of SufE is located close to this loop and forms a hydrogen 
bond with Gln54, which may stabilize the loop orientation of the active site Cys51 at the 
resting state. We mutated Asp74 to Arg to break this hydrogen bond. The result shows a 
better affinity of SufE_D74R to SufS. The interaction of SufS and SufE shows oxidative 
resistance. To check if SufE_D74R still keeps this ability, we constructed MG1655 ΔsufE. 
The plasmid pET21a containing sufE_D74R was transformed into this strain. The final 
optical density at 600 nm (growth) of MG1655 ΔsufE and MG1655 
ΔsufE/pET21a_sufD74R was measured after 20 hours in M9 gluconate minimal media with 
increasing concentrations of phenazine methosulfate (a generator of oxidative stress) 
(Figure A1). MG1655 ΔsufE/pET21a_sufE was added into this experiment as a control. A 
second control is the MG1655 ΔsufE strain containing the empty plasmid pET21a. The 
results show that SufE D74R still keeps the ability of oxidative resistance in vivo. 
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Figure A.1. Growth experiment of MG1655 ΔsufE/pET21a_sufE_D74R in the presence 
of oxidative stress. 
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            Sulfur transfer from SufE to SufB 
            The active site Cys51 of SufE accepts the sulfide from the active site Cys364 of 
SufE to become a persulfide, which is subsequently transferred to the SufB that is the Fe-
S cluster scaffold protein. This transfer of persulfide recycles SufE to participate in another 
reaction cycle with SufS. So SufBC2D further enhances the activity of the sulfur 
mobilization of the SufS-SufE complex. However, the interaction between SufE and SufB 
is not well characterized at the structural level. To address this question, we alkylated 
SufBC2D with iodoacetamide (IAA) to covalently block the solvent accessible free thiols 
on the surface that may accept persulfide from SufE. After IAA treatment, 13 of the 18 
total thiols were alkylated and did not react with DTNB (Figure A2). The alkylated 
SufBC2D cannot enhance the activity of SufS and SufE (Figure A3).  The alkylated 
SufBC2D cannot form Fe-S clusters when it incubated with SufS, SufE, and L-cysteine 
(Figure A4). When we added Na2S as the sulfur source, Fe-S clusters were formed (Figure 
A5).   
            Among the 13 thiols alkylated by IAA, MS/MS analysis revealed that 9 Cys from 
SufB, 1 Cys from SufD, and 2 Cys from the SufC dimer. The 5 cys residues protected from 
the alkylation based on the DTNB analysis and MS/MS are Cys332, Cys405, Cys414 from 
SufB and Cys295, Cys358 from SufD (Figure A6). We hypothesized that the Cys inside 
SufB may transfer sulfur from the surface to the location of Fe-S cluster formation. So we 
mutated both Cys405 and Cys414 to Ala (SufBC2D C405A/C414A) and checked if the 
mutant SufBC2D can still enhance the activity of SufS-SufE (Figure A7). The result shows 
that this mutant SufBC2D can still enhance the activity of SufS-SufE. There are two  
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Figure A.2. DTNB-detectable thiols in IAA-modified or unmodified SufBC2D measured 
under native or denaturing conditions. DTNB is a reagent that reacts with thiol group to 
yield a colored product, providing a reliable method to measure the number of the reductive 
Cys residues in protein. 
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Figure A.3. Enhancement of SufS-SufE cysteine desulfurase activity with SufBC2D () 
or SufBC2Dalk (). 
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Figure A.4. Fe-S cluster reconstitution on SufBC2D (red line) or SufBC2Dalk (blue line) 
using SufS-SufE-L-cysteine as sulfur source.  
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Figure A.5. Fe-S cluster reconstitution on SufBC2D (red line) or SufBC2Dalk (blue line) 
using Na2S as sulfur donors. 
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Figure A.6.  Unalkylated Cys residues in SufBC2D.  (A)  Cys residues that were 
resistant to IAA modification identified by MS and MS/MS are mapped on the 
SufBC2D structural model in space filling.  (B)  Close up view of the SufB‒SufD 
interface where several of these protected cysteines are localized. 
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Figure A.7. Desulfurase activity of SufS and SufE in function of SufBC2D. The mutant 
SufBC2D is SufBC2D C405A/C414A. 
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possible explanations. The first is that Cys405 and Cys414 are not relative to sulfur 
transfer. The second is that the surface Cys of this mutant SufBC2D still accepts sulfur 
from SufE, which enhance the desulfurase activity. Further experiments are needed to 
clarify the role of Cys405 and Cys414 in the formation of Fe-S cluster. 
 
            Desulfurase activity of SufS-SufE in low/high activity SufBC2D 
            We found that SufBC2D can be divided into low activity and high activity 
according to the difference of its ATPase activity. We incubated SufS, SufE, and either 
low activity SufBC2D or high activity SufBC2D before we checked the desulfurase activity 
(Figure A8). The result showed both low and high activity SufBC2D can enhance the 
desulfurase activity of SufS-SufE. However, the low activity SufBC2D shows better 
enhancement than that of the high activity SufBC2D. The meaning of low/high ATPase 
activity of SufBC2D is still under research.  
 
            Influence of pH to the desulfurase activity of SufS-SufE 
            To detect the influence of pH to the desulfurase activity of SufS-SufE, we checked 
the activity of 0.5 uM SufS and 2uM SufE under various pH of the buffer (Figure A9). The 
result shows that the activity of SufS-SufE increases following the increasing of pH. The 
protein collapses under pH 10. In the reaction mechanism, there are two steps that needs 
deprotonation. The first step is that external aldimine loses a proton to become a quinonoid 
intermediate. The second step of deprotonation is that the active site Cys364 loses a proton 
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to accept the sulfide from ketimine. So the increased pH helps the deprotonation process, 
which enhance the desulfurase reaction. 
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Figure A.8: Desulfurase activity of SufS-SufE in function of high/low activity of 
SufBC2D. 
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Figure A.9. pH titration of desulfurase activity of SufS and SufE.  
